Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives by Briguglio, Irene et al.
Accepted Manuscript
Synthesis, cytotoxicity and antiviral evaluation of new series of
imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives
Irene Briguglio, Roberta Loddo, Erik Laurini, Maurizio Fermeglia, Sandra Piras, Paola
Corona, Paolo Giunchedi, Elisabetta Gavini, Giuseppina Sanna, Gabriele Giliberti,
Cristina Ibba, Pamela Farci, Paolo La Colla, Sabrina Pricl, Antonio Carta
PII: S0223-5234(15)30284-1
DOI: 10.1016/j.ejmech.2015.10.002
Reference: EJMECH 8137
To appear in: European Journal of Medicinal Chemistry
Received Date: 7 July 2014
Revised Date: 1 October 2015
Accepted Date: 3 October 2015
Please cite this article as: I. Briguglio, R. Loddo, E. Laurini, M. Fermeglia, S. Piras, P. Corona,
P. Giunchedi, E. Gavini, G. Sanna, G. Giliberti, C. Ibba, P. Farci, P. La Colla, S. Pricl, A. Carta,
Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and
pyrido[2,3-g]quinoxalinone derivatives, European Journal of Medicinal Chemistry (2015), doi: 10.1016/
j.ejmech.2015.10.002.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Synthesis, cytotoxicity and antiviral evaluation of new series of 
imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives 
 
Irene Briguglioa§, Roberta Loddob*§, Erik Laurinic§, Maurizio Fermegliac, Sandra Pirasa, Paola Coronaa, Paolo 
Giunchedia, Elisabetta Gavinia, Giuseppina Sannab, Gabriele Gilibertib, Cristina Ibbab, Pamela Farcib, Paolo 
La Collab+, Sabrina Priclcd+, Antonio Cartaa*+ 
aDipartimento di Chimica e Farmacia, Università degli Studi di Sassari, Via Muroni 23/A, 07100 Sassari, 
Italy 
 bDipartimento di Scienze Biomediche, Sezione di Microbiologia e Virologia, Università degli Studi di 
Cagliari, Cittadella Universitaria s.p.8, Km 0,700, 09042 Monserrato (Ca), Italy 
cMolecular Simulation Engineering (MOSE) Laboratory, Department of Engineering and Architecture 
(DEA), University of Trieste, 34127 Trieste, Italy 
dNational Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-
DEA, University of Trieste, 34127 Trieste, Italy 
§These authors contributed equally to this work 
+Senior co-authors 
Keywords: imidazo[4,5-g]quinolines, pyrido[2,3-g]quinoxalines, antiviral activity, RNA viruses, 
DNA viruses. 
*Corresponding Authors: 
Tel.: +39 079 228722; fax: +39 079 228720. E.mail address acarta@unisss.it; 
Tel.: +39 070 6754202; fax: +39 070 6754210. E.mail address rloddo@unica.it 
 
Abstract 
Linear aromatic N-tricyclic compounds with promising antiviral activity and minimal cytotoxicity 
were prepared and analyzed in the last years. Specifically, the pyrido[2,3-g]quinoxalinone nucleus 
was found endowed with high potency against several pathogenic RNA viruses as etiological agents 
of important veterinary and human pathologies. Following our research program on new antiviral 
agents we have designed, synthesized and assayed new series of imidazo[4,5-g]quinoline and 
pyrido[2,3-g]quinoxalinone derivatives. Lead compounds 1-4 were further modified to enhance 
their antiviral activity and reduce their cytotoxicity. Thus, different substituents were introduced on 
N atom at position 1 or the O atom at position 2 of the leads; contextually, several groups were 
inserted on the nitrogen atom at position 7 of diaminoquinoline intermediates. Title compounds 
were tested in cell-based assays for cytotoxicity and antiviral activity against RNA virus families 
containing single-stranded (either positive-sense (ssRNA+) or negative-sense (ssRNA-)), and 
double-stranded genomes (dsRNA), and against two representatives of DNA virus families. Some 
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derivatives emerged as potential leads for further development as antiviral agents against some 
viruses of public health significance, such as RSV, Reo, BVDV and HCV. Particularly, compounds 
4, 11b, 11c, 13c, 15a, 18 and 21 resulted active against BVDV at concentrations ranging from 1.3 
to 5 µM. Compound 21 was also evaluated for its activity on the BVDV RdRp. Compound 4 was 
also tested as potential anti-HCV compound in a subgenomic replication assay. Molecular 
simulation results provided a molecular rationale for the anti-BVDV activity of these compounds. 
 
1. Introduction 
Over 200 species of DNA and RNA viruses are known to be able to infect and cause significant 
diseases in humans [1, 2]. Examples of DNA pathogen viruses are Herpesviruses, e.g., Herpes 
simplex virus type 1 (HSV-1) and Poxviruses [3], which can infect both vertebrate and invertebrate 
animals, or, from Orthopoxvirus genus the Vaccinia virus (VV). The latter emerged in recent years 
for its potential use as an attractive bioterrorist weapon [4]. This menace to public health increased 
our awareness around human vulnerability to this infection, especially since smallpox vaccination 
was discontinued in 1980 [5-9]. RNA viruses include many highly pathogens affecting humans, 
several of them showing the ability to cross the species barrier and resulting in zoonotic-human 
epidemics [10]. Examples of RNA pathogen viruses are Flaviviruses, which can cause life-
threatening diseases in both humans and animals. This virus family includes three genera: 
Pestiviruses, Flaviviruses and Hepaciviruses. The Pestivirus genus includes animal pathogens of 
major economic impact for the livestock industry, such as the Bovine viral diarrhea virus (BVDV). 
Hepatitis C virus (HCV) is the sole representative of the Hepacivirus genus and constitutes the 
major cause of human hepatitis per se [11]. Other important RNA viruses belong to the 
Picornaviridae family. These viruses induce a variety of maladies including meningitis, cold, heart 
infection, conjunctivitis, and hepatitis. This family includes nine genera, some of which comprise 
major human pathogens (e.g., Poliovirus and Coxsackievirus) [12]. At present, no specific antiviral 
therapy is available for the treatment of Picornaviridae infections. 
In this scenario, there is an urgent need for new lead compounds that either target distinct stages of 
the viral replication cycle in a virus-specific way, have a broader spectrum of activity or act through 
novel mechanisms of action. In this context, according to a long-lasting antiviral research program 
our group designed and synthesized three new classes of linear aromatic N-tricyclic compounds 
endowed with promising antiviral activity and selectivity index against several pathogenic RNA 
viruses: triazolo[4,5-g]quinolines, imidazo[4,5-g]quinolones, and pyrido[2,3-g]quinoxalines [13]. 
All three molecular classes share the same key intermediate: a 6,7-diaminoquinoline scaffold 
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variously substituted on the nitrogen at position 7. Specifically, the pyrido[2,3-g]quinoxalinone 
nucleus was found particularly active against the Pestivirus BVDV and partly against the Human 
respiratory syncytial virus (RSV). Both these two viruses are of major interest for livestock and 
human therapies, respectively. In antiviral drug discovery, BVDV is commonly used as a surrogate 
model for Hepatitis C virus [14]. Thus, given their interesting activity against BVDV, the 
pyrido[2,3-g]quinoxalinones were also tested against HCV in a subgenomic replication assay that 
allows viral replication in a human hepatoma cell line (GS4.1). Furthermore, the lead compounds of 
that series were evaluated in enzyme assays performed with the recombinant BVDV and HCV 
RNA-dependent RNA polymerases (RdRps) [13]. Unfortunately, both the pyrido[2,3-
g]quinoxalines and pyrido[2,3-g]quinoxalinones resulted more active against the BVDV than the 
HCV enzyme. Moreover, they showed slight cytotoxicity against several cell lines.  
In the light of these results, and with the aim of enhancing the antiviral activity and reducing the 
cytotoxicity of these molecules, in this work we selected lead compounds 1 and 2 from the previous 
molecular series (Fig. 1), which bear a phenyl and a benzyl substituent at position 3 of the 
pyrazinone moiety, respectively, for further development. Furthermore, we adopted derivative 3, 
which contains an isopropyl side chain at the same position and is totally devoid of activity on all 
tested viruses and cell lines, as a negative benchmark. Finally, as shown in Scheme 1, we 
synthesized and assayed the thienyl derivative 4 since no derivative bearing a heterocycle moiety at 
position 3 was previously reported and its intermediate 4b is readily available on the market.  
 
This study is divided in three parts. In the first part we modified the structure of lead compound 1 
by inserting a propyl, cyclohexyl or methylcyclohexyl group on the nitrogen at position 7 of the 
diaminoquinoline intermediates 8a-c, as reported in Scheme 2.  
Unexpectedly, the subsequent cyclization reaction with 2-oxo-2-phenylacetic acid provided, in 
addition to the desired pyrido[2,3-g]quinoxalinone derivatives with the phenyl ring at position 2 
(11a-c), the imidazo[4,5-g]quinolines 9a,b. Interestingly, the same molecular scaffold was obtained 
in the past by another chemical route [13]. To verify the reproducibility of this mechanism the 
diaminoquinolines 8b,c were submitted to cyclization reaction with 2-oxo-2-(thiophen-2-yl) acetic 
and 2-oxo-3-phenylpropanoic acids, respectively. In the first case both the pyrido[2,3-
g]quinoxalinone bearing the thiophene ring at position 2 (12b) and the corresponding imidazo[4,5-
g]quinoline 10b were obtained. In the second case the reaction afforded the pyrido[2,3-
g]quinoxalinone 13c and only non-isolable traces of the corresponding imidazo[4,5-g]quinoline 9c. 
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In the second part of this study we introduced several substituents - methyl, ethyl, acetonitrile, 
benzyl and 4-nitrobenzyl group - either on the nitrogen atom at position 1 or on the oxygen atom at 
position 2, as shown in Scheme 3. Through direct alkylation of compound 1, N-alkyl derivatives 
(14a-e) were always obtained, while the isomeric O-derivatives were not always obtained. 
Antiviral evaluation of the N and O alkyl derivatives 14 and 15 highlighted N-methyl (14a) and O-
methyl (15a) derivatives as the only compounds endowed of antiviral activity against BVDV, with 
EC50 values for compound 15a comparable to that of lead compound 1. Moreover, these compounds 
showed activity also against CVB-5 and Sb-1 (14a), RSV and Reo-1 (15a) viruses. 
Consequently, we submitted the other three lead compounds (2, 3 and 4) only to a methylation 
reaction to dissect the relevance of the different substituents at position 3, as shown in Scheme 4.  
All synthesized compounds were tested for cytotoxicity and for activity in cell-based assays against 
ssRNA+ viruses [Human immunodeficiency virus (HIV-1), Coxsackie virus type B5 (CVB-5), Polio 
virus (Sb-1), Yellow Fever virus (YFV), Bovine Viral Diarrhea virus (BVDV)], ssRNA- viruses 
[Human respiratory syncytial virus (RSV), Vescicular stomatitis virus (VSV)], dsRNA viruses 
[Reovirus (Reo-1)], and DNA viruses [(Herpes simplex virus type 1 (HSV-1), Vaccinia virus (VV)], 
with the aim of comparing their antiviral activity with that of the former molecular series. In 
addition, compound 4 was submitted to the HCV subgenomic replication assay to assess the activity 
of this new lead compound against this critical human pathogen. Finally, a molecular-base rationale 
for the anti-BVDV activity of these compounds is proposed based on the results of computer-based 
simulations. 
All viruses selected were among those most harmful to human health. With the exception of YFV, 
there is no vaccine available against the above-mentioned Flaviviruses to date, and only a few new 
drugs are currently under successful pre-clinical development in this field [12, 15-19]. This 
perspective indeed emphasizes the compelling need for the identification of new molecules with 
therapeutic potential against RNA viruses.  
2. Results and discussion 
2.1 Chemistry 
The synthetic route to obtain compound 4 is illustrated in Scheme 1. The key intermediate 8-
chloroquinoline-6,7-diamine 4a, obtained as reported in [20], was submitted to cyclization reaction 
with 2-oxo-2-(thiophen-2-yl)acetic acid (4b) in 10% sulfuric acid to give the expected 5-chloro-3-
(thiophen-2-yl)pyrido[2,3-g]quinoxalin-2(1H)-one (4) (yield 43%) but not the 2-thiophen-2-yl 
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isomer (4c). As shown in Scheme 1 and previously reported in [21], the reaction conditions 
determine its regioselectivity. In fact, the simultaneous presence of the acidic environment and an 
electron-withdrawing group on the α-carbonyl of 4b leads to the exclusive formation of the desired 
isomer 4. 
The diamine intermediates 8a-c, crucial for the preparation of quinoxalines 11a-c, 12b and 13c, 
were generally obtained in good yield through nucleophilic substitution of the chlorine at position 7 
of the known 7,8-dichloro-6-nitroquinoline (5) [22] with the amines 6a-c. The nitro derivatives 
intermediates (7a-c) were subsequently submitted to reduction reaction with 10% Pd/C in ethanol, 
as depicted in Scheme 2.  
The succeeding condensation reaction of the diamines 8a-c with the appropriate α-ketoacids in 
refluxed ethanol led not only to the expected pyrido[2,3-g]quinoxalinones (11a-c, 12b and 13c), but 
also to the imidazo[4,5-g]quinolines derivatives 9a-c and 10b. This behavior is somewhat different 
from that previously discussed for compound 4. In fact, the lack of an acidic environment and the 
presence of an alkyl group on the nitrogen at position 7 of the diaminoquinolines 8a-c - which 
increase the steric hindrance around that site - both reverse the reactivity providing only the 2-aryl 
isomers 11a-c, 12b and 13c. On the other hand, this reaction is in competition with the formation of 
the imidazo[4,5-g]quinoline nucleus, as previously reported by our group [21]. 
Scheme 3 reports the synthesis of the pyrido[2,3-g]quinoxalinones 14a-e and pyrido[2,3-
g]quinoxalines 15a,b,e. The lead compound 1 was subjected to alkylation reaction with methyl and 
ethyl sulfate, acetonitrile, benzyl bromide and 4-nitrobenzyl chloride in dimethylformamide (DMF) 
and Cs2CO3 at 60 °C for 1-16 hours. From these reactions the expected N alkyl derivatives (14a-e) 
were isolated, with yields ranging from 67% to 95%. When the alkylating agents were methyl and 
ethyl sulfate or 4-nitrobenzyl chloride, even O-alkyl derivatives (15a,b,e) were isolated, even if the 
yields in this case were rather low (7% - 23%).  
Finally, as confirmation of the observed behavior, the methylation of the remaining lead compounds 
(2-4) provided both products of N-alkylation and O-alkylation with yields of 26-30% (16-18) and 
13-23% (19-21), respectively (Scheme 4). 
2.2 Biology 
Title compounds were evaluated in cell-based assays for cytotoxicity and antiviral activity against 
ssRNA+ viruses representative of the Flaviviridae and Picornaviridae families. In particular, 
representative viruses of two of the three genera of the Flaviviridae family, YFV (Flaviviruses) and 
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BVDV (Pestiviruses), and one genus of the Picornaviridae family, CVB-5 and Sb-1 
(Enteroviruses), were tested. Compounds were also tested against other representatives of ssRNA+, 
ssRNA- and DNA viruses. 
Table 1 shows the overall results of the cell-based assays obtained for imidazo[4,5-g]quinolines 
(9a-c and 10b), pyrido[2,3-g]quinoxalinones (4, 11a-c, 12b, 13c, 14a-e, 16-18) and pyrido[2,3-
g]quinoxalines (15a,b,e, 19-21). Efavirenz (EFV), 2′-C-methyl-guanosine (Met-Gua), 2′-C-methyl-
cytidine (Met-Cyt), 2′-C-ethynyl-cytidine (Eth-Cyt), 6-azauridine (Aza), cidofovir (CDF) and 
acyclovir (ACG) were used as reference compounds. As concerns the antiviral activity, none of title 
compounds turned out to be active against HIV-1, YFV, VSV, VV and HSV-1, although some (9a, 
11a, 14a) show a modest and scattered activity against CVB-5 and Sb-1. On the contrary, 
compounds belonging to all classes proved to be endowed with an interesting anti-BVDV activity. 
Among these compounds (bold in Table 1), only 9c, 11a, 11c, and 13cexerted cytotoxic effects on 
exponentially growing MT-4 cell lines, and on MDBK and BHK cells in stationary growth, at 
concentrations ≤ 40µM. However, as expected, the imidazo[4,5-g]quinolines derivatives showed 
only moderate activity against BVDV. Indeed, in a previous paper our research group demonstrated 
the need of the presence of a chlorine atom on the quinoline ring for activity against this virus [13]. 
Conversely, pyrido[2,3-g]quinoxalines derivatives exhibited moderate to good activity towards 
BVDV, especially when an aryl substituent at position 3 is present in addition to the chlorine atom 
at position 5.  
Among lead compounds, thienyl derivative 4 showed BVDV selectivity, good potency and  
selectivity index. For this reason, compound 4 was also tested as potential anti-HCV compound in a 
subgenomic replication assay. Experimental results (Table 2) showed that 4 was indeed able to 
inhibit HCV replication (EC50 = 7.5 ±0.5 µM), but was also cytotoxic for GS4.1 cells (CC50 = 21 ± 
2.0 µM), overall resulting in poor selectivity index (S.I. ≈ 3). 
Biological analysis further confirmed that N-alkylated and O-alkylated derivatives were in general 
devoid of cytotoxicity. Among them, compounds 18 and 21 not only show activity greater than the 
corresponding unmethylated lead 4 but also are the most potent and selective molecules against 
BVDV with EC50 values of 2 and 1.3 µM, respectively. 
Compound 21 was finally evaluated for its activity on the BVDV RdRp (Figure 2). In vitro 
enzymatic assay demonstrated that this compound inhibits the BVDV RNA-dependent RNA 
polymerase activity with an IC50 value of 0.64 µM, thus confirming both compound potency and 
viral target protein. 
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2.3 Modeling results 
Previous enzymatic assays clearly showed that the lead compounds 1 and 2 [13] and 21 target one 
of the most important enzymes involved in the BVDV replication-cycle, namely the RNA-
dependent RNA-polymerase (RdRp). Molecular simulation studies were then performed on a subset 
of 12 present compounds including the leads 1-4 with two specific purposes: i) to dissect the effect 
of the substitution of the quinoxalin-2(1H)-one scaffold in the corresponding N-methylated 
compounds 14a and 16-18 or the 2-methoxy-quinoxaline moiety in compounds 15a and 19-21; and 
ii) the role of a bulky aromatic substituent at position 3 of the double-nitrogen ring. For this 
purpose, a preliminary search for a putative binding site for our compounds on the BVDV RdRp 
was first conducted [23-28]. In line with previous findings [26-28], the resulting portion of the 
enzyme making up the binding pocket for our molecular set is located between the RdRp Fingers 
domains 1 and 2 (residues 139–313 and 351–410, Figure 3A). Accordingly, all molecules were 
docked within the selected protein cavity according to a well-validated procedure, and the 
corresponding protein/drug free energies of binding (∆Gbind) were scored by applying molecular 
dynamics (MD) simulations based on the MM/PBSA approach [23-34]. Table 3 shows the result of 
the MM/PBSA analysis, from which a direct correlation between enzyme/drug affinity and in vitro 
EC50 values is apparent. As seen in this Table, computational data confirm that lead compounds 1, 2 
and 4 all bind the BVDV polymerase with highly comparable affinity, while compound 3, chosen as 
negative reference, does not. The critical presence of a bulky aromatic substituent at position 3 of 
all compounds for their optimal BVDV RdRp binding is also confirmed by the other data in Table 
3. Indeed, for both series of compounds 14a,16-18 and 15a,19-21 a marked decrease in the value of 
∆Gbind is predicted when an isopropyl group is found at that position. 
To investigate in more detail the BVDV RdRp binding mode of these selected compounds, we 
proceeded and analyzed the main interactions involved in the stabilization of the relevant 
enzyme/drug complexes. Taking the quinoxaline derivative 21 as proof-of-concept, the analysis of 
the corresponding equilibrated MD trajectory reveals that 21 is nestled in the detected RdRp 
binding pocket, where it occupies two cavities lined by the side chains of residues A221, I261, I287, 
and Y289 and residues V216, Y303, V306, K307, P408 and A412, respectively (Figure 3B). 
Contextually, three stabilizing hydrogen bonds (HBs) are identified between donor atoms on the 
side chain of protein residues R295, S411 and Y674 are the corresponding counterparts in the 
compound structure represented by the N-pyrido atom, the nitrogen atom at position 1 of the 
quinozaline moiety, and the sulfur atom of the thienyl ring, respectively (Figure 3B). 
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A quantitative analysis of the drug/protein interaction was performed via a per-residue 
deconvolution of the enthalpic contribution to binding afforded by each single residue involved [32-
38], as reported in Table 4. To facilitate reading, the values of ∆Hbind,res for the critical RdRp 
residues were clustered according to a specific underlying interaction type as follows: A221, I261, 
I287, and Y289 belong to the first hydrophobic cavity (HC1), and were considered for hydrophobic 
(HI) and π-interactions (π). Analogously, amino acids V216, Y303, V306, K307, P408 and A412 
were clustered in the other hydrophobic cavity (HC2) and considered for analogous interaction 
types. On the other hand, R295, Y674 and S411, as responsible for H-bond interactions, were 
classified as HB1, HB2, and HB3, respectively. 
The permanent hydrogen bond between the N-pyrido atom of 21 and the side chain of R295 (HB1, 
average dynamic length (ADL) = 1.96 ± 0.05 Å) reflects in a stabilizing contribution of -2.03 
kcal/mol. Concomitantly, the second stable H-bond interaction detected between the hydroxyl 
group of Y674 and the quinoxaline nitrogen atom (HB2, average dynamic length (ADL) = 1.94 ± 
0.03 Å) provides a favorable contribution to binding of -1.98 kcal/mol. The third polar interaction 
HB3, involving the –OH on the side chain of S411 and the S atom of the thiophene ring of 21 is 
decidedly weaker, as confirmed by its ∆Hbind,res value of -0.58 and the corresponding longer ADL 
(2.15 ± 0.05 Å). Finally, the network of HI and π interactions, originated among the aromatic 
portions of 21 and the two identified receptor cavities HC1 and HC2, considerably concur in 
stabilizing the protein/drug binding with an overall contribution of -5.95 kcal/mol.  
With the aim of finding a molecular rationale for the points i) and ii) above, the same computational 
analysis was then applied to all remaining 11 compounds in Table 3. As can be seen by 
reconsidering all ∆Gbind values listed in this Table, the modification of the amide group in lead 
compounds 1-4 did not substantially affect their binding affinity towards the target protein. Taking 
the thienyl derivatives 4, 18, and 21 as proof-of-concept, the relevant ∆Gbind values are all very 
similar, being in the range -8.00 ÷ -8.19 kcal/mol (Table 3). In keeping with these results, the same 
compound trio exhibits an utterly comparable interactions profile against the RdRp of BVDV, as 
confirmed by their interaction spectra (Figure 4A) and their binding pose (Figure 4B).  
It is worth noting how the interactions involving the second hydrophobic cavity (HC2) are not 
negligible, as they afford a stabilization to compound binding comparable to those originating from 
HC1. Further, taking the quinoxaline series as a meaningful example, the corresponding interaction 
spectra in Figure 5A well illustrate the importance of the presence of a bulky, aromatic substituent 
able to fulfill the HC2 HI and π network. As indeed illustrated in Figure 5A, both the phenyl and 
benzyl derivatives 15a and 19 respectively show a similar interactions spectra compared to the best 
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compound 21; this, in turn, reflects in a good estimated affinity against the target RdRp (Table 3). 
Notably, the presence of a further polar interaction in the thienyl derivative 21 (HB3) is not a 
pivotal requirement for BVDV RdRp binding, but it can be eventually exploited to optimize it. On 
the other hand, the isopropyl group in compound 20 is too small to aptly fit the second hydrophobic 
cavity: this is reflected in a plummet of both its RdRp binding affinity (Table 3) and (even more so) 
in the relevant interactions with each residue involved in the binding site (Figure 5A). Furthermore, 
since the small aliphatic substituent cannot establish the required network of hydrophobic and π 
interactions with the side chains of the residues belonging to the HC2, the compound assumes an 
ineffective pose, which, in turn, exerts a negative influence also on the remaining portion of the 
BVDV RdRp binding site (Figure 5A-B). 
2.4 Computer Aided Drug Design 
Based on the computational results reported in Section 2.3, we designed 4 new potential BVDV 
RdRp inhibitors. Focusing on the position 3 of the molecular scaffold, we propose the replacement 
of the thienyl ring of lead compound 21 with other (hetero)cyclic entities theoretically able to fulfill 
the determined network of intermolecular interactions. For this purpose, the following moieties 
were selected: 2-Furanyl (23), 2-Naphtyl (24), and 2-Benzofuranyl (25). Compound 22, featuring a 
cyclohexyl as the substituent, was also included in the design as a sort of negative control. In fact, 
based on the results obtained for 20, we surmised that the presence of a flexible moiety with no 
heteroatoms available for hydrogen bonding with the enzyme and with a non-aromatic character 
should ultimately result in a drop of the corresponding enzyme/drug affinity. Applying the same 
computational protocol, we docked compounds 22-25 in the enzyme binding site and calculated the 
corresponding enzyme affinity (∆Gbind). As seen from Table 5, the new derivatives 23-25 are 
endowed with excellent BVDV affinities (-8.43, -8.14, and -8.72 kcal/mol, respectively), whereas 
compound 22 shows a remarkable lower ∆Gbind value (-6.36 kcal/mol), as expected.       
From the deconvolution of the enthalpic component of the binding free energy (∆Hbind, Figure 6A), 
the higher affinity of the furanyl derivatives 23 compared to 21 is justified by a shorter and stronger 
hydrogen bond detected between the oxygen atom and the hydroxyl group of S411 (ADL = 2.08 ± 
0.04 Å). while all other interactions within the protein binding site remain unperturbed. 
Contextually, in the case of compound 24, the lack of HB3 pharmacophoric requirement is 
compensated by an improvement of the hydrophobic and p interaction network, ultimately resulting 
in the preservation of the drug affinity towards BVDV RdRp (Figure 6A). Compound 25 represents 
the best structural combination in that the oxygen atom of the furanyl group is engaged in a strong 
H-bond with S411 (ADL = 2.06 ± 0.03 Å) whereas the aromatic portion of the moiety is nicely 
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encased in the HC2, thereby increasing the strength of the specific hydrophobic interactions (Figure 
6A). Figure 6B shows a comparison of the binding mode of compounds 21 and 25 within the 
BVDV RdRP binding pocket. 
 
3. Conclusions 
In this work, starting from a set of lead compounds 1-4, different series of molecules based on the 
5-chloro-pyrido[2,3-g]quinoxalin-2(1H)-one nuclei have been synthesized, tested as antiviral agents 
on a series of RNA- and DNA-viruses. Overall, the results suggest that this tricyclic nuclei appear 
to be interesting scaffolds in the drug discovery and development processes of new antiviral agents 
actives against important animal and human pathogens such as BVDV and HCV.  
Specifically, biological evaluation of N-methylated (14a, 16-18) and O-methylated (15a, 19-21) 
derivatives demonstrated that these compounds are endowed with good anti-BVDV activity only 
when they bear a phenyl or a thienyl group at position 3. Molecular modeling studies confirmed that 
some modifications in the structure of the synthesized quinoxalinones 1-4 are beneficial in 
decreasing the lead compound toxicity profiles without affecting their affinity against their target 
polymerase. Additionally, and maybe more important from drug development point of view, the 
computational approach allowed to identify important molecular determinants for the BVDV RdRp 
binding that could be exploited to further optimize the structure of new derivatives provided with a 
more potent antiviral activity. Accordingly, further developments could interest position 3 either 
through the introduction of different electron donor or electron withdrawing substituents on the 
phenyl moiety or its replacement with other heterocycles able to fulfill the determined network of 
intermolecular interactions. In this perspective, we designed and tested in silico 4 new derivatives 
(22-25) featuring different (hetero)cyclic substituents at position 3 of the general molecular 
scaffold. The results confirmed that compounds 23-25, which can preserve or ameliorate the 
network of protein/drug intermolecular interactions, are endowed with a high affinity towards the 
viral enzyme. On the other hand, the free energy of binding for compound 22 plummets in the 
presence of a flexible, cycloaliphatic group as a result of a global detriment of the corresponding 
interaction network. The synthesis and the subsequent evaluation of the antiviral activity of 
compounds 23-25 are in progress in order to develop and characterize a new series of a more potent 
BVDV RdRp inhibitors. More, compound 21 is currently undergoing assays to test its druggability 
profile. 
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4. Experimental 
4.1. Chemistry 
4.1.1. General remarks 
Melting points were carried out with a Köfler hot stage or Digital Electrothermal melting point 
apparatus and are uncorrected. Infrared spectra were recorded as nujol mulls with a Perkin-Elmer 
781 IR spectrophotometer and are expressed in  (cm-1). Nuclear magnetic resonance (1H-NMR) 
spectra were determined in CDCl3, DMSO-d6, CDCl3/DMSO-d6 (1:3 ratio) and were recorded with a 
Bruker Avance III 400 NanoBay. Chemical shifts ( scale) are reported in parts per million (ppm) 
downfield from tetramethylsilane (TMS) used as internal standard. Splitting patterns are designated, 
as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; br s, broad singlet; dd, double 
doublet. The assignment of exchangeable protons (OH and NH) was confirmed by the addition of 
D2O. 
13C NMR were determined in DMSO-d6 and were recorded at 100 MHz with Bruker Avance III 400 
NanoBay. Ms spectra were performed on combined Liquid Chromatograph-Agilent 1100 series 
Mass Selective Detector (MSD). Analytical thin-layer chromatography (TLC) was performed on 
Merck silica gel F-254 plates. Pure compounds showed a single spot in TLC. For flash 
chromatography, Merck silica gel 60 was used with a particle size 0.040-0.063 mm (230-400 mesh 
ASTM). Elemental analysis were performed on a Perkin-Elmer 2400 instrument at Laboratorio di 
Microanalisi, Dipartimento di Chimica e Farmacia, Università degli studi di Sassari, Italy, and the 
results were within ±0.4% of theoretical values. 
 
4.1.2. Starting material and known intermediates 
The intermediates 8-Chloro-N-cyclohexylquinoline-6,7-diamine (7b), 8-chloroquinoline-6,7-
diamine (4a) and 7,8-dichloro-6-nitroquinoline (5) were prepared according to procedure previously 
reported by us [13, 20, 22]. 2-Oxo-2-(thiophen-2-yl)acetic acid (4b), propan-1-amine (6a), 
cyclohexanamine (6b), cyclohexylmethanamine (6c), were commercially available. 
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4.1.3. 5-chloro-3-(thiophen-2-yl)pyrido[2,3-g]quinoxalin-2(1H)-one (4) 
The intermediate, 6,7-diamino-8-chloroquinoline (4a) (2.06 mmol) of scheme 1, was dissolved in 8 
mL of H2SO4 10% followed by the addition of 2.06 mmol of 2-oxo-2-(thiophen-2-yl)acetic acid 
(4b). The mixture was heated at 60°C under stirring for 1h. After cooling, the orange crude 
precipitate was filtered off and purified by flash chromatography over silica gel eluting with a 9:1 
mixture of chloroform/methanol (43% yield); m.p. >300°C (from EtOH); IR (nujol):  3300, 1672 
cm-1; 1H NMR (CDCl3 + DMSO-d6):  12.90 (1H, br s, NH), 9.00 (1H, d, J = 4.4 Hz, H-7), 8.58 
(1H, d, J = 4.8 Hz, H-5’), 8.43 (1H, d, J = 8.4 Hz, H-9), 7.82 (1H, d, J = 3.6 Hz, H-3’), 7.73 (1H, s, 
H-10), 7.62 (1H, dd, J = 8.4 and 4.4 Hz, H-8), 7.26 (1H, dd, J = 4.8 Hz and 3.6 Hz, H-4’). 13C-NMR 
(DMSO-d6): δ 121.2 (CH), 122.3 (CH), 123.3 (C),124.3 (CH), 125.3 (C), 126.4 (CH), 126.2 (CH), 
127.3 (C),132.2 (CH), 133.8 (C),135.2 (C), 139.8 (C),144.8 (CH), 154.2 (C), 156.3 (C). LC/MS: m/z 
316 [M + 1]. Anal. Calcd. for C15H8ClN3OS: C, 57.42; H, 2.57; N, 13.39; found C, 57.28; H, 2.49; 
N, 13.28. 
 
4.1.4. General procedure for the preparation of the intermediates 7a,c.  
To a solution of 7,8-dichloro-6-nitroquinoline (5) (1 g, 4.1 mmol) in DMF (10 mL) an excess of the 
required substituted amines 6a,c (16 mmol) was added dropwise with stirring. The solution was then 
stirred for further 8 h at 100°C. After cooling, water was added (10 mL) and the solution was 
extracted with CHCl3. The organic extracts were dried on sodium sulfate, filtered, and the 
chloroform solution concentrated under reduced pressure. The oil residues were purified by flash 
chromatography eluting with a 8:2 mixture of petroleum ether/ethyl acetate. 
 
4.1.4. 1. 8-Chloro-6-nitro-N-propylquinolin-7-amine (7a) This compound was obtained in 25% yield 
by the protocol above described; m.p. 91-93 °C (from EtOH); IR (nujol):  3388, 1612, 1525, 1345, 
cm-1; 1H NMR (CDCl3):  9.05 (1H, dd, J = 4.2 and 1.6 Hz, H-2), 8.37 (1H, s, H-5), 8.14 (1H, dd, J 
= 8.2 and 1.6 Hz, H-4), 7.35 (1H, dd, J = 8.2 and 4.2 Hz, H-3), 5.94 (1H, br s, NH), 3.36 (2H, m, 
NH-CH2-CH2-CH3), 1.78-1.60 (2H, m, NH-CH2-CH2-CH3), 0.99 (3H, t, J = 7.4 Hz, CH3). 13C-NMR 
(CDCl3): δ 11.0 (CH3), 22.2 (CH2), 46.0 (CH2), 114.8 (C), 121.5 (C), 122.5 (CH), 124.0 (CH), 137.6 
(CH), 137.8 (C), 139.5 (C), 142.5 (C), 154.2 (CH). LC/MS: m/z 268 [M + 1]. Anal. Calcd. for 
C12H12ClN3O2: C, 54.25; H, 4.55; N, 15.82; found C, 54.05; H, 4.68; N, 15.69. 
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4.1.4. 2. 8-Chloro-N-(cyclohexylmethyl)-6-nitroquinolin-7-amine (7c) 
This compound was obtained in 58% yield by the protocol above described; m.p. 87-89 °C (from 
EtOH); IR (nujol):  3404, 1613, 1525, 1345, cm-1; 1H NMR (CDCl3):  9.04 (1H, dd, J = 4.2 and 
1.6 Hz, H-2), 8.34 (1H, s, H-5), 8.13 (1H, dd, J = 8.2 and 1.6 Hz, H-4), 7.34 (1H, dd, J = 8.2 and 4.2 
Hz, H-3), 5.97 (1H, br s, NH), 3.20 (2H, t, CH2), 1.76-0.9 (11H, m, cyclohexyl).13C-NMR (CDCl3): 
δ 24.8 (2 x CH2), 26.2 (CH2), 30.8 (2 x CH2), 37.7 (CH), 54.0 (CH2), 113.8 (C), 120.8 (C), 121.70 
(CH), 123.1 (CH), 136.9 (CH), 137.0 (C), 138.7 (C), 142.3 (C), 153.6 (CH). LC/MS: m/z 322 [M + 
1]. Anal. Calcd. for C16H18ClN3O2: C, 60.09; H, 5.67; N, 13.14; found C, 60.32; H, 5.38; N, 13.40. 
 
4.1.5. General procedure for the preparation of the diamines 8a,c. 
The 8-chloro-N-(substituted)-6-nitroquinolin-7-amines 7a,c (2.07 mmol) were dissolved in 70 mL of 
ethanol followed by the addition of 10% Palladium on activated charcoal. This mixture was 
hydrogenated in Parr at 20-25°C at 3 atm. After filtering and washing the catalyst thoroughly with 
ethanol, the filtrates were concentrated in vacuo to give the desired intermediates 8a,c. 
 
4.1.5.1. 8-Chloro-N7-propylquinoline-6,7-diamine (8a) 
This compound was obtained, as an oil, in 90% yield by the protocol described in the general 
procedure starting from 7a (550 mg, 2.07 mmol); IR (nujol):  3450, 3330, 3240 cm-1; 1H NMR 
(CDCl3):  8.73 (1H, dd, J = 4.2 and 1.6 Hz, H-2), 7.86 (1H, dd, J = 8.2 and 1.6 Hz, H-4), 7.25 (1H, 
dd, J = 8.2 and 4.2 Hz, H-3), 6.87 (1H, s, H-5), 4.25 (3H, br s, NH), 3.13 (2H, t, J = 7.2 Hz, N-CH2), 
1.73-1.60 (2H, m, CH2-CH3), 1.03 (3H, t, J = 7.2 Hz, CH3). 13C-NMR (CDCl3): δ 11.0 (CH3), 23.2 
(CH2), 46.3 (CH2), 111.8 (C), 117.8 (CH), 118.9 (CH), 122.5 (C), 130.6 (CH), 132.9 (C), 133.6 (C), 
136.2 (C), 144.0 (CH). LC/MS: m/z 238 [M + 1]. Anal. Calcd. for C12H14ClN3: C, 61.15; H, 5.99; N, 
17.83; found C, 61.01; H, 5.88; N, 17.66. 
 
4.1.5.2. 8-chloro-N7-(cyclohexylmethyl)quinoline-6,7-diamine (8c)  
This compound was obtained in 42% yield by the protocol described in the general procedure 
starting from 7c (662 mg, 2.07 mmol) after flash chromatography, eluting with a 8:2 mixture of 
petroleum ether/ethyl acetate.M.p. 88-90 °C (from EtOH); IR (nujol):  3425, 3298, 3250 cm-1; 1H 
NMR (CDCl3):  8.74 (1H, dd, J = 4.4 and 1.6 Hz, H-2), 7.87 (1H, dd, J = 8.2 and 1.6 Hz, H-4), 
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7.24 (1H, dd, J = 8.0 and 4.4 Hz, H-3), 6.86 (1H, s, H-5), 4.24 (3H, br s, NH), 2.94 (2H, d, J = 7.4 
Hz, CH2) 1.95-1.04 (11H, m, cyclohexyl). 13C-NMR (CDCl3): δ 24.6 (2 x CH2), 25.8 (CH2), 30.0 (2 
x CH2), 37.0 (CH), 54.7 (CH2), 111.0 (C), 117.3 (CH), 118.0 (CH), 121.8 (C), 130.5 (CH), 132.8 
(C), 132.0 (C), 136.2 (C), 144.2 (CH). LC/MS: m/z 292 [M + 1]. Anal. Calcd. for C16H20ClN3: C, 
66.31; H, 6.96; N, 14.50; found C, 66.17; H, 7.16; N, 14.22. 
 
4.1.6. General procedure for the preparation of 2,3-substituted 3H-imidazo[4,5-g]quinolines 9a-c, 
10b and the 5-chloro-2,4-substituted-pyrido[2,3-g]quinoxalin-3(4H)-ones 11a-c, 12b and 13c. 
A solution of the quinolines (8a-c) (1.38 mmol) in ethanol (6 mL) was obtained by heating under 
reflux, then an excess of either required acids (2-oxo-2-phenylacetic acid, 2-oxo-2-(thiophen-2-yl) 
acetic acid or 2-oxo-3-phenylpropanoic acid) was added. Heating was maintained for different times 
as reported below. After cooling, the solution was evaporated and the crude products were purified 
by flash chromatography using as eluent a mixture of petroleum ether/ethyl acetate or acetone in 
different ratios, as reported below. The imidazo[4,5-g]quinolines 9a, 9b, 9c, and 10b were obtained 
associated with the pyrido[2,3-g]quinoxalines 11a, 11b, 13c, and 12b, respectively.  
 
4.1.6.1. 2-Phenyl-3-propyl-3H-imidazo[4,5-g]quinoline (9a) and 5-chloro-2-phenyl-4-
propylpyrido[2,3-g]quinoxalin-3(4H)-one (11a) 
9a was obtained in 66% yield by the protocol described in the general procedure starting from 8a 
(367 mg, 1.38 mmol) and 2-oxo-2-phenylacetic acid (228 mg, 1.52 mmol) for 12h. The reaction 
mixture was purified by silica gel column chromatography eluting with a 7:3 mixture of petroleum 
ether/ethyl acetate. M.p. 128-130 °C (from EtOH); TLC (petroleum ether/ethyl acetate 7:3): Rf 0.10; 
IR (nujol):  1652 cm-1; 1H NMR (CDCl3):  8.91 (1H, dd, J = 3.8 and 1.6 Hz, H-6), 8.36 (1H, dd, J 
= 8.1 and 1.6 Hz, H-8), 8.24 (1H, s, H-4), 8.13 (1H, s, H-9), 7.82-7.77 (2H, m, H-2’, 6’), 7.59-7.55 
(3H, m, H-3’, 4’, 5’), 7.33 (1H, dd, J = 8.1 and 3.8 Hz, H-7), 4.32 (2H, t, J = 7.6 Hz, N-CH2), 2.01-
1.90 (2H, m, CH2-CH3), 0.91 (3H, t, J = 7.4 Hz, CH3). 13C-NMR (CDCl3): δ 11.4 (CH3), 22.3 (CH2), 
51.7 (CH2), 109.7 (CH), 116.9 (CH), 118.4 (CH), 124.3 (C), 128.7 (2 x CH), 129.6 (2 x CH), 130.3 
(CH), 130.9 (C), 136.3(CH), 136.9 (C), 143.6 (C), 144.6 (C), 150.0 (CH), 158.4 (C). LC/MS: m/z 
288 [M + 1]. Anal. Calcd. for C19H17N3: C, 79.41; H, 5.96; N, 14.62; found C, 79.19; H, 5.86; N, 
14.96. 
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11a was obtained from 8a in 4% yield by the protocol above described. M.p. 100-102 °C (from 
EtOH); TLC (petroleum ether/ethyl acetate 7:3): Rf 0.24; IR (nujol):  1742, 1627 cm-1; 1H NMR 
(CDCl3):  9.06 (1H, dd, J = 4.4 and 2.0 Hz, H-7), 8.36 (1H, dd, J = 8.2 and 2.0 Hz, H-9), 8.19 (1H, 
s, H-10), 7.79-7.74 (2H, m, H-2’, 6’), 7.60-7.57 (3H, m, H-3’, 4’, 5’), 7.44 (1H, dd, J = 8.2 Hz and J 
= 4.4 Hz, H-8), 4.66 (2H, t, J = 7.4 Hz, N-CH2), 1.93-1.80 (2H, m, CH2-CH3), 0.79 (3H, t, J = 7.4 
Hz, CH3). 13C-NMR (CDCl3): δ 11.2 (CH3), 19.90 (CH2), 44.1 (CH2), 113.0 (C), 109.9 (CH), 123.0 
(CH), 128.2 (C), 130.1 (2 x CH), 129.7 (2 x CH), 129.4 (C), 130.8 (CH), 134.8 (CH), 138.2 (C), 
139.0 (C), 143.0 (C), 151.8 (CH), 155.4 (C), 156.0 (C). LC/MS: m/z 352 [M + 1]. Anal. Calcd. for 
C20H16ClN3O: C, 68.67; H, 4.61; N, 12.01; found C, 68.39; H, 4.49; N, 11.79. 
 
4.1.6.2. 3-Cyclohexyl-2-phenyl-3H-imidazo[4,5-g]quinoline (9b) and 5-chloro-4-cyclohexyl-2-
phenylpyrido[2,3-g]quinoxalin-3(4H)-one (11b) 
9b was obtained in 57% yield by the protocol described in the general procedure starting from 8b 
(380 mg, 1.38 mmol) and 2-oxo-2-phenylacetic acid (228 mg, 1.52 mmol) for 12h. The reaction 
mixture was purified by silica gel column chromatography eluting with a 7:3 mixture of petroleum 
ether/ethyl acetate;m.p. 183-185 °C (from EtOH); TLC (petroleum ether/ethyl acetate 7:3): Rf 0.11; 
IR (nujol):  1654 cm-1;1H NMR (CDCl3):  8.90 (1H, dd, J = 4.2 and 1.6 Hz, H-6),8.45 (1H, s, H-
9), 8.36 (1H, dd, J = 8.8 and 1.6 Hz, H-8), 8.26 (1H, s, H-4), 7.74-7.70 (2H, m, H-2’, 6’), 7.60-7.56 
(3H, m, H-3’, 4’, 5’), 7.36 (1H, dd, J = 8.8 and 4.2 Hz, H-7), 4.42 (1H, m, cyclohexyl), 2.60-1.25 
(10H, m, cyclohexyl). 13C-NMR (CDCl3): δ 25.1 (CH2), 25.9 (2 x CH2), 30.8 (2 x CH2), 57.4 (CH), 
110.2 (CH), 116.3 (CH), 118.8 (CH), 124.50 (C), 128.8 (2 x CH), 129.4 (2 x CH), 130.3 (CH), 130.4 
(C), 136.7 (CH), 136.9 (C), 143.7 (C), 144.1 (C), 149.3 (CH), 158.8 (C). LC/MS: m/z 328 [M + 1]. 
Anal. Calcd. for C22H21N3: C, 80.70; H, 6.46; N, 12.83; found C, 80.50; H, 6.30; N, 12.67. 
11b was obtained from 8b in 8% yield by the protocol above described. M.p. 169-170 °C (from 
EtOH); TLC (petroleum ether/ethyl acetate 7:3): Rf 0.21; IR (nujol):  1716, 1633 cm-1; 1H NMR 
(CDCl3):  9.07 (1H, dd, J = 4.4 and 1.6 Hz, H-7), 8.35 (1H, dd, J = 8.2 and 1.6 Hz, H-9), 8.17 (1H, 
s, H-10), 7.79-7.60 (2H, m, H-2’, 6’), 7.59-7.45 (3H, m, H-3’, 4’, 5’), 7.42 (1H, dd, J = 8.2 and 4.4 
Hz, H-8), 4.23 (1H, m, cyclohexyl), 2.20-1.10 (10H, m, cyclohexyl). 13C-NMR (CDCl3): δ 24.9 
(CH2), 26.4 (2 x CH2), 33.5 (2 x CH2), 58.7 (CH), 109.4 (CH), 123.6 (CH), 127.4 (C), 128.5 (2 x 
CH), 129.4 (2 x CH), 129.8 (C), 130.3 (CH), 130.8 (C), 135.7 (C), 136.8 (CH), 137.4 (C), 141.4 (C), 
149.8 (CH), 153.0 (C), 160.8 (C). LC/MS: m/z 392 [M + 1]. Anal. Calcd. for C23H20ClN3O: C, 
70.85; H, 5.17; N, 10.78; found C, 70.62; H, 5.02; N, 10.56. 
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4.1.6.3. 2-Benzyl-3-(cyclohexylmethyl)-3H-imidazo[4,5-g]quinoline (9c) and 2-benzyl-5-chloro-4-
cyclohexylpyrido[2,3-g]quinoxalin-3(4H)-one (13c) 
9c was obtained in 9 % yield by the protocol described in the general procedure starting from 8c 
(399 mg, 1.38 mmol) and 2-oxo-3-phenylpropanoic acid (249 mg, 1.52 mmol) for 6h. The reaction 
mixture was purified by silica gel column chromatography eluting with a 8.5:1.5 mixture of 
petroleum ether/aceton; m.p. 67-69 °C (from EtOH); TLC (petroleum ether/aceton 8.5:1.5): Rf 0.16; 
IR (nujol):  3451, 2360, 1632, 1600 cm-1; 1H NMR (CDCl3):  8.87 (1H, dd, J = 4.2 and 1.8 Hz, H-
6), 8.33 (1H, dd, J = 8.4 and 1.8 Hz, H-8), 8.17 (1H, s, H-9), 8.00 (1H, s, H-4), 7.37-7.20 (6H, m, H-
7 and H-Ph), 4.41 (2H, s, CH2-Ph), 3.94 (2H, d, J = 7.6 Hz, N-CH2-cyclohexyl), 2.00-0.85 (11H, m, 
cyclohexyl). 13C-NMR (CDCl3): δ 25.6 (2 x CH2), 26.0 (CH2), 31.1 (2 x CH2), 38.0 (CH), 31.1 
(CH2), 50.6 (CH2), 107.2 (CH), 115.8 (CH), 118.6 (CH), 127.2 (CH), 128.5 (2 x CH), 128.9 (2 x 
CH), 124.6 (C), 135.6 (C), 136.81 (CH), 139.1 (C), 142. 7 (C), 144.5 (C), 149.2 (CH), 158.7 (C). 
LC/MS: m/z 356 [M + 1]. Anal. Calcd. for C24H25N3: C, 81.09; H, 7.09; N, 11.82; found C, 79.90; 
H, 7.06; N, 11.64. 
13c was obtained from 8c in 33 % yield by the protocol above described. M.p. 53-55 °C (from 
EtOH); TLC (petroleum ether/aceton 8.5:1.5): Rf 0.25; IR (nujol):  1740, 1604 cm-1; 1H NMR 
(CDCl3):  9.05 (1H, dd, J = 4.4 and 1.6 Hz, H-7), 8.38 (1H, dd, J = 8.2 and 1.6 Hz, H-9), 8.19 (1H, 
s, H-10), 7.37-7.20 (6H, m, H-8 and H-Ph), 4.41 (2H, s, N-CH2), 3.94 (2H, s, CH2-Ph), 2.00-0.85 
(11H, m, cyclohexyl). 13C-NMR (CDCl3): δ 24.9 (CH2), 26.1 (2 x CH2), 33.80 (2 x CH2), 52.6 
(CH2), 57.5 (CH2), 58.8 (CH), 109.9 (CH), 123.1 (CH), 126.8 (C), 128.0 (2 x CH), 129.7 (2 x CH), 
129.3 (C), 130.4 (C), 130.9 (CH), 136.1 (C), 136.3 (CH), 137.7 (C), 141.0 (C), 150.4 (CH), 153.6 
(C), 155.2 (C). LC/MS: m/z 420 [M + 1]. Anal. Calcd. for C25H24ClN3O: C, 71.85; H, 5.79; N, 
10.05; found C, 71.59; H, 5.97; N, 10.29. 
 
4.1.6.4. 3-Cyclohexyl-2-(thiophen-2-yl)-3H-imidazo[4,5-g]quinoline (10b) and 5-chloro-4-
cyclohexyl-2-(thiophen-2-yl)pyrido[2,3-g]quinoxalin-3(4H)-one (12b) 
10b was obtained in 8% yield by the protocol described in the general procedure starting from 8b 
(380 mg, 1.38 mmol) and 2-oxo-2-(thiophen-2-yl)acetic acid (237 mg, 1.52 mmol) for 12h. The 
reaction mixture was purified by silica gel column chromatography eluting with a 6:4 mixture of 
petroleum ether/ethyl acetate; m.p. 152-154 °C (from EtOH); TLC (petroleum ether/ethyl acetate 
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7:3): Rf 0.15; IR (nujol):  2360, 1671 cm-1; 1H NMR (CDCl3):  8.89 (1H, dd, J = 4.0 and 1.6 Hz, 
H-6), 8.39 (1H, s, H-4), 8.32 (1H, dd, J = 8.0 and 1.6 Hz, H-8), 8.22 (1H, s, H-9), 7.63 (1H, d, J = 
5.2 Hz, H-5’), 7.48 (1H, d, J = 3.8 Hz, H-3’), 7.32 (1H, dd, J = 8.0 and 4.0 Hz, H-7), 7.25 (1H, dd, J 
= 5.2 and 3.8 Hz, H-4’), 4.79 (1H, m, cyclohexyl), 2.72-2.50 (2H, m, cyclohexyl), 2.06-1.42 (8H, m, 
cyclohexyl). 13C-NMR (CDCl3): δ 25.6 (CH2), 26.0 (2 x CH2), 32.0 (2 x CH2), 57.9 (CH), 105.0 
(CH), 121.3 (CH), 126.70 (C), 127.1 (CH), 128.5 (CH), 128.70 (C), 128.6 (CH), 129.2 (CH), 129.10 
(C), 136.0 (CH), 138.1 (C), 143.7 (C), 149.8 (CH), 158.8 (C). LC/MS: m/z 334 [M + 1]. Anal. 
Calcd. for C20H19N3S: C, 72.04; H, 5.74; N, 12.60; found C, 71.88; H, 5.52; N, 12.85. 
12b was obtained from 8b in 30 % yield by the protocol above described. M.p. 215-217 °C (from 
EtOH); TLC (petroleum ether/ethyl acetate 7:3): Rf 0.26; IR (nujol):  2368, 1744, 1679 cm-1; 1H 
NMR (CDCl3):  9.07 (1H, dd, J = 4.4 and 1.6 Hz, H-7), 8.34 (1H, dd, J = 8.2 and 1.6 Hz, H-9), 
8.16 (1H, s, H-10), 7.63 (1H, dd, J = 5.0 and 1.0 Hz, H-5’), 7.57 (1H, dd, J = 4.0 and 1.0 Hz, H-3’), 
7.43 (1H, dd, J = 8.2 and 4.4 Hz, H-8), 7.24 (1H, dd, J = 5.0 and 4.0 Hz, H-4’), 4.28 (1H, m, 
cyclohexyl), 2.72-1.32 (10H, m, cyclohexyl). 13C-NMR (CDCl3): δ 24.9 (2 x CH2), 25.6 (CH2), 31.1 
(2 x CH2), 60.9 (CH), 113.0 (C), 109.2 (CH), 120.3 (CH), 123.8 (C), 124.1 (C), 125.3 (CH), 127.1 
(CH), 127.3 (CH), 134.9 (CH),137.6 (C), 138.3 (C),139.4 (C),149.3 (CH), 152.4 (C), 159.0 (C). 
LC/MS: m/z 398 [M + 1]. Anal. Calcd. for C21H18ClN3OS: C, 63.71; H, 4.58; N, 10.61; found C, 
63.98; H, 4.26; N, 10.85. 
 
4.1.6.5. 5-chloro-4-(cyclohexylmethyl)-2-phenylpyrido[2,3-g]quinoxalin-3(4H)-one (11c) 
This compound was obtained in 68 % yield by the protocol described in the general procedure 
starting from 8c (399 mg, 1.38 mmol) and 2-oxo-2-phenylacetic acid (228 mg, 1.52 mmol) for 2h 
and 45’; the compound was purified by silica gel column chromatography eluting with a 6:4 mixture 
of petroleum ether/ethyl acetate; m.p. 129-131 °C (from EtOH); IR (nujol):  1732, 1627, 1604 cm-1; 
1H NMR (CDCl3):  9.05 (1H, dd, J = 4.4 and 1.6 Hz, H-7), 8.38 (1H, dd, J = 8.2 and 1.6 Hz, H-9), 
8.19 (1H, s, H-10), 7.80-7.72 (2H, m, H-2’, 6’), 7.62-7.50 (3H, m, H-3’, 4’, 5’), 7.41 (1H, dd, J = 8.2 
and 4.4 Hz, H-8), 4.59 (2H, d, J = 7.2 Hz, CH2), 4.12 (1H, m, cyclohexyl), 1.95-0.85 (10H, m, 
cyclohexyl). 13C-NMR (CDCl3): δ 25.3 (2 x CH2), 25.9 (CH2), 30.9 (2 x CH2), 45.1 (CH), 48.3 
(CH2), 115.9 (CH), 119.0 (CH), 126.1 (C), 128.2 (2 x CH), 129.9 (2 x CH), 130.4 (C), 131.1 (CH), 
130.2 (C), 136.3 (C), 136.8 (CH), 138.4 (C), 142.1 (C), 148.9 (CH), 154.2 (C), 159.5 (C). LC/MS: 
m/z 406 [M + 1]. Anal. Calcd. for C24H22ClN3O: C, 71.37; H, 5.49; N, 10.40; found C, 71.06; H, 
5.68; N, 10.14. 
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4.1.7. General procedure for the preparation of 5-chloro-1-substituted-3-phenylpyrido[2,3-
g]quinoxalin-2(1H)-ones 14a-e and the 5-chloro-2-substituted-3-phenylpyrido[2,3-g]quinoxalines 
15 a,b,e. 
To a mixture of the 5-chloro-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (1) [13] (492 mg, 1.60 
mmol) and Cs2CO3(521 mg, 1.60 mmol)) in anhydrous N,N-dimethylformammide (DMF) (10 mL) 
an excess of the required alkylant agents (dimethyl sulfate, diethyl sulfate, bromomethylbenzene, 1-
chloromethyl-4-nitrobenzene) (1.60-7.07 mmol) in N,N-dimethylformammide (5-10 mL) was added 
dropwise. The mixture was stirred at 60°C for 1-16h, then allowed to cool to room temperature and 
water (50 mL) was added. The resulting precipitates were collected by filtration, washed with water 
and the crude products were purified by flash chromatography using a mixture of ethyl 
ether/methanol as eluent in different ratios as reported below. The 1-substituted-pyrido[2,3-
g]quinoxalin-2(1H)-ones 14a,b,ewere obtained associated with the 2-substituted-pyrido[2,3-
g]quinoxalines 15a,b,e respectively.  
 
4.1.7.1. 5-Chloro-1-methyl-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (14a) and 5-chloro-2-
methoxy-3-phenylpyrido[2,3-g]quinoxaline (15a) 
14a was obtained in 77 % yield by the protocol described in the general procedure starting from 1 
(492 mg, 1.60 mmol), Cs2CO3(521 mg, 1.60 mmol) and dimethyl sulfate (393 mg, 3.12 mmol) in 
DMF (10 mL) for 16h; the mixture was purified by silica gel column chromatography eluting with a 
9.5:0.5 mixture of ethyl ether/methanol; m.p. 256-258 °C (from EtOH); TLC (petroleum 
ether/aceton 8.5:1.5): Rf 0.65; IR (nujol):  1651, 1624 cm-1; 1H NMR (CDCl3):  9.00 (1H, d, J = 
4.4 Hz, H-7), 8.52 (1H, d, J = 8.6 Hz, H-9), 8.17 (1H, d, J = 8.6 Hz, H-8), 7.60-7.45 (5H, m, H-Ph), 
7.42 (1H, s, H-10), 3.78 (3H, s, CH3). 13C-NMR (CDCl3): δ 35.3 (CH3), 109.1 (CH), 122.9 (CH), 
128.1 (2 x CH), 128.7 (C), 129.2 (2 x CH), 130.8 (C), 131.5 (CH), 133.4 (C), 135.8 (C), 136.9 (CH), 
137.9 (C), 139.2 (C), 150.0 (CH), 152.8 (C), 153.7 (C). LC/MS: m/z 324 [M + 1]. Anal. Calcd. for 
C18H12ClN3O: C, 67.19; H, 3.76; N, 13.06; found C, 67.03; H, 3.45; N, 12.96. 
15a was obtained from 1in 19 % yield by the protocol above described. M.p. 148-150 °C (from 
EtOH); TLC (petroleum ether/aceton 8.5:1.5): Rf 0.46; IR (nujol):  1732, 1665 cm-1; 1H NMR 
(DMSO-d6):  1H NMR (DMSO-d6):  9.13 (1H, d, J = 4.2 Hz, H-7), 8.35 (1H, d, J = 8.2 Hz, H-9), 
8.26 (1H, s, H-10), 8.10 (2H, m, H-2’, 6’), 7.53 (4H, m, H-8, H-3’, 4’, 5’), 4.23 (3H, s, CH3). 13C-
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NMR (DMSO-d6): δ 54.3 (CH3), 120.5 (CH), 123.9 (CH), 126.1 (C), 127.0 (2 x CH), 128.3 (CH), 
129.0 (2 x CH), 130.1 (CH), 130.8 (CH), 131.2 (C), 131.9 (C), 134.8 (C), 136.0 (CH), 140.1 (C), 
150.1 (CH), 151.9 (C), 154.0 (C). LC/MS: m/z 324 [M + 1]. Anal. Calcd. for C18H12ClN3O: C, 
67.19; H, 3.76; N, 13.06; found C, 67.06; H, 3.54; N, 12.84. 
 
4.1.7.2. 5-chloro-1-ethyl-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (14b) and 5-chloro-2-ethoxy-
3-phenylpyrido[2,3-g]quinoxaline (15b) 
14b was obtained in 71 % yield by the protocol described in the general procedure starting from 1 
(492 mg, 1.60 mmol), Cs2CO3 (521 mg, 1.60 mmol) and diethyl sulfate(284 mg, 1.84 mmol) in 
DMF (10 mL) for 4h; the mixture was purified by silica gel column chromatography eluting with a 
9:1 mixture of ethyl ether/methanol; m.p. 252-253 °C (from EtOH); TLC (petroleum ether/aceton 
8.5:1.5): Rf 0.70; IR (nujol):  1664, 1597 cm-1; 1H NMR (CDCl3):  1H NMR (DMSO-d6):  9.00 
(1H, s, H-7), 8.51 (1H, d, J = 7.6 Hz, H-9), 8.39 (2H, m, H-2’, 6’), 8.09 (1H, s, H-10), 7.60 (4H, m, 
H-8, H-3’, 4’, 5’), 4.38 (2H, q, J = 6 Hz, CH2), 1.48 (3H, s, t, J = 7.2 Hz, CH3). 13C-NMR (DMSO-
d6): δ 11.9 (CH3), 37.6 (CH2), 109.3 (CH), 123.1 (CH), 127.9 (2 x CH), 128.2 (C), 129.0 (2 x CH), 
130.9 (C), 131.0 (CH), 131.2 (C), 132.6 (C), 135.5 (C), 136.2 (CH), 139.9 (C), 151.0 (CH), 153.1 
(C), 154.8 (C). LC/MS: m/z 338 [M + 1]. Anal. Calcd. for C19H14ClN3O: C, 67.96; H, 4.20; N, 
12.51; found C, 68.31; H, 4.08; N, 12.88. 
15b was obtained from 1 in 23 % yield by the protocol above described. M.p. 160-162 °C (from 
EtOH); TLC (petroleum ether/aceton 8.5:1.5): Rf 0.38; IR (nujol):  1733, 1669 cm-1; 1H NMR 
(DMSO-d6):  9.04 (1H, d, J = 4.2 Hz, H-7), 8.51 (1H, d, J = 8.4 Hz, H-9), 8.27 (1H, s, H-10), 8.17 
(2H, m, H-2’, 6’), 7.48 (4H, m, H-8, H-3’, 4’, 5’), 4.55 (2H, q, J = 6.8 Hz, CH2), 1.33 (3H, t, J = 6.8 
Hz, CH3). 13C-NMR (DMSO-d6): δ 13.9 (CH3), 63.3 (CH2), 122.2 (CH), 122.7 (CH), 127.8 (C), 
128.18 (2 x CH), 128.8 (C), 129.9 (2 x CH), 130.5 (CH), 131.0 (CH), 131.2 (C), 132.6 (C), 135.5 
(C), 136.2 (CH), 139.9 (C), 151.0 (CH), 153.1 (C), 154.8 (C). LC/MS: m/z 338 [M + 1]. Anal. 
Calcd. for C19H14ClN3O: C, 67.96; H, 4.20; N, 12.51; found C, 67.63; H, 4.08; N, 12.22. 
 
4.1.7.3. 5-chloro-1-(4-nitrobenzyl)-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (14e) and 5-chloro-
2-(4-nitrobenzyloxy)-3-phenylpyrido[2,3-g]quinoxaline (15e) 
14e was obtained in 67 % yield by the protocol described in the general procedure starting from 1 
(492 mg, 1.60 mmol), Cs2CO3 (521 mg, 1.60 mmol) and 1-(chloromethyl)-4-nitrobenzene (806 mg, 
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4.70 mmol) in DMF (10 mL) for 4h; the mixture was purified by silica gel column chromatography 
eluting with a 9:1 mixture of ethyl ether/methanol; m.p. 268-270 °C (from EtOH); TLC (petroleum 
ether/aceton 8.5:1.5): Rf 0.61; IR (nujol):  1652, 1602 cm-1; 1H NMR (CDCl3):  1H NMR 
(DMSO-d6):  9.09 (1H, d, J = 4.4 Hz, H-7), 8.51 (1H, d, J = 7.2 Hz, H-9), 8.61 (2H, m, H-2’, H-6’ 
Ph), 8.22 (2H, d, J = 8.0 Hz, H-3’, H-5’ benzyl), 8.10 (1H, s, H-10),7.69 (2H, d, J = 8.4 Hz, H-2’, 
H-6’ benzyl), 7.60 (4H, m, H-8, H-3’, H-4’, H-5’ Ph), 7.28, 5.75 (2H, s, CH2). 13C-NMR (DMSO-
d6): δ 45.5 (CH2), 109.6 (CH), 123.2 (CH), 123.6 (2 x CH), 128.0 (2 x CH), 128.1 (2 x CH), 128.8 
(C), 130.0 (2 x CH), 131,1 (C), 131.15 (CH), 131.7 (C), 132.9 (C), 135.9 (C), 136.1 (CH), 140.1 
(C), 143.4 (C), 146.7 (C), 151,1 (CH), 153.8 (C), 154.9 (C). LC/MS: m/z 445 [M + 1]. Anal. Calcd. 
for C24H15ClN4O3: C, 65.09; H, 3.41; N, 12.65; found C, 64.91; H, 3.28; N, 12.39. 
15e was obtained from 1 in 7 % yield by the protocol above described. M.p. 221-223 °C (from 
EtOH); TLC (petroleum ether/aceton 8.5:1.5): Rf 0.25; IR (nujol):  1698, 1642 cm-1; 1H NMR 
(DMSO-d6):  9.19 (1H, d, J = 4.4 Hz, H-7), 8.73 (2H, m, H-2’, H-6’ Ph), 8.45 (2H, d, J = 8.6 Hz, 
H-3’, H-5’ benzyl), 8.10 (1H, d, = 8.2 Hz, H-9), 8.02-7.85 (5H, m, H-8, H-10, H-3’, H-4’, H-5’ Ph), 
7.36 (2H, d, J = 8.6 Hz, H-2’, H-6’ benzyl), 5.91 (2H, s, CH2). 13C-NMR (DMSO-d6): δ 51.9 (CH2), 
121.8 (CH), 124.1 (CH), 124.0 (2 x CH), 126.8 (C), 127.6 (2 x CH), 128.6 (2 x CH), 128.6 (CH), 
129.1 (2 x CH), 131.4 (C), 131.8 (C), 135.0 (C), 137.9 (C), 136.4 (CH), 138.6 (C), 142.6 (C), 144.1 
(C), 146.6 (C), 150.3 (CH), 153.3 (C). LC/MS: m/z 445 [M + 1]. Anal. Calcd. for C24H15ClN4O3: C, 
65.09; H, 3.41; N, 12.65; found C, 64.91; H, 3.23; N, 12.88. 
4.1.7.4. 2-(5-chloro-2-oxo-3-phenylpyrido[2,3-g]quinoxalin-1(2H)-yl)acetonitrile (14c) 
To a solution of the 5-chloro-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (1) (492 mg, 1.60 mmol) 
in 2-chloroacetonitrile (12.63 mL) was added Cs2CO3 (658 mg, 2.02 mmol). The reaction was 
stirred at 60°C for 1h and then allowed to cool to room temperature. Water (50 mL) was added and 
the resulting precipitate was collected by filtration, washed with water and dried in a oven to give a 
crystalline solid. Yield: 95 %; m.p. 293-295 °C (from EtOH); IR (nujol):  1653, 1602 cm-1; 1H 
NMR (DMSO-d6):  1H NMR (DMSO-d6):  9.09 (1H, d, J = 4.4 Hz, H-7), 8.55 (1H, d, J = 8.6 
Hz, H-9), 8.39-8.26 (2H, m, H-2’, H-6’), 8.24 (1H, s, H-10), 7.75 (1H, dd, J = 8.6 Hz and J = 4.4 
Hz, H-8), 7.60-7.44 (3H, m, H-3’, 4’, 5’), 4.08 (2H, s, CH2). 13C-NMR (DMSO-d6): δ 30.8 (CH2), 
109.2 (CH), 115.2 (C), 123.6 (CH), 128.11 (2 x CH), 128.8 (C), 129.9 (2 x CH), 130.8 (C), 131.3 
(CH), 133.1 (C), 135.0 (C), 136.14 (CH), 140.4 (C), 151.4 (CH), 153.0 (C), 154.5 (C). LC/MS: m/z 
349 [M + 1]. Anal. Calcd. for C19H11ClN4O: C, 65.81; H, 3.20; N, 16.16; found C, 65.54; H, 3.42; 
N, 16.02. 
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4.1.7.5. 1-benzyl-5-chloro-3-phenylpyrido[2,3-g]quinoxalin-2(1H)-one (14d) 
This compound was obtained in 30 % yield by the protocol described in the general procedure 
starting from 1 (492 mg, 1.60 mmol), Cs2CO3 (521 mg, 1.60 mmol) and (bromomethyl)benzene 
(1209 mg, 0.84 mL, 7.07 mmol) in DMF (10 mL) for 4h; m.p. 228-230 °C (from EtOH); IR (nujol): 
 1663, 1597 cm-1; 1H NMR (DMSO-d6):  9.06 (1H, d, J = 4.4 Hz, H-7), 8.62 (2H, m, H-Ph), 8.12 
(1H, d, J = 8.2 Hz, H-9), 7.50-7.30 (10H, m, H-8, H-10, H-Ph + benzyl), 5.56 (2H, s, CH2). 13C-
NMR (DMSO-d6): δ 45.7 (CH2), 109.8 (CH), 123.1 (CH), 126.9 (2 x CH), 127.3 (CH), 128.0 (2 x 
CH), 128.4 (2 x CH), 128.6 (CH), 129.8 (2 x CH), 131,0 (C), 131.6 (C), 132.8 (C), 135.4 (C), 136.1 
(C), 139.9 (C), 151,08 (CH), 153.7 (C), 154.9 (C). LC/MS: m/z 400 [M + 1]. Anal. Calcd. for 
C24H16ClN3O: C, 72.45; H, 4.05; N, 10.56; found C, 72.15; H, 3.87; N, 10.26. 
 
4.1.8. General procedure for the preparation of 5-chloro-1-methyl-3-phenylpyrido[2,3-
g]quinoxalin-2(1H)-ones (16-18) and the 5-chloro-2-methoxy-3-phenylpyrido[2,3-g]quinoxalines 
(19-21). 
To a mixture of the opportune 5-chloro-3-(thiophen-2-yl)pyrido[2,3-g]quinoxalin-2(1H)-one (4), 
prepared as above reported, (502 mg, 1.60 mmol), 3-benzyl-5-chloropyrido[2,3-g]quinoxalin-2(1H)-
one (2) [1] (515 mg, 1.60 mmol), and 5-chloro-3-isopropylpyrido[2,3-g]quinoxalin-2(1H)-one (3) 
[13] (438 mg, 1.60 mmol) and one mole equivalent of Cs2CO3 in anhydrous N,N-
dimethylformammide (10 mL) was dropwise added an excess of dimethyl sulfate (393 mg, 3.12 
mmol) in N,N-dimethylformammide (10 mL). The mixture was stirred at 60°C for 16h, then allowed 
to cool to room temperature and water (50 mL) was added. The resulting precipitates were collected 
by filtration, washed with water and the crude products were purified by flash chromatography using 
a mixture of ethyl ether/methanol 95:5 as eluent. The 1-methyl-pyrido[2,3-g]quinoxalin-2(1H)-
ones(16-18) were obtained associated with the 2-methoxy-pyrido[2,3-g]quinoxalines(19-21) 
respectively.  
 
4.1.8.1. 3-benzyl-5-chloro-1-methylpyrido[2,3-g]quinoxalin-2(1H)-one (16) and 3-benzyl-5-chloro-
2-methoxypyrido[2,3-g]quinoxaline (19) 
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16 was obtained in 26 % yield by the protocol described in the general procedure starting from 2 
[13]. M.p. 275-277 °C (from EtOH); IR (nujol):  3315, 1652, 1607 cm-1; 1H NMR (DMSO-d6):  
9.56 (1H, d, J = 4.6 Hz, H-7), 9.35 (1H, d, J = 8.6 Hz, H-9), 9.01 (1H, s, H-10), 8.61 (2H, m, H-2’, 
6’), 7.89 (1H, dd, J = 8.6 and 4.6 Hz, H-8), 7.71 (3H, m, H-3’, 4’, 5’), 3.84 (2H, s, CH2), 3.60 (3H, s, 
CH3). 13C-NMR (DMSO-d6): δ 37.5 (CH3), 44.8 (CH2), 109.3 (CH), 123.5 (CH), 125.3 (CH), 126.1 
(C), 127.8 (C), 128.4 (2 x CH), 128.9 (2 x CH), 131.7 (C), 133.5 (CH), 134.1 (C), 136.1 (C), 140.6 
(C), 145.8 (CH), 154.6 (C), 155.3 (C). LC/MS: m/z 338 [M + 1]. Anal. Calcd. for C19H14ClN3O: C, 
67.96; H, 4.20; N, 12.51; found C, 67.67; H, 4.37; N, 12.27. 
19 was obtained from 2in 23 % yield by the protocol above described. M.p. 158-160 °C (from 
EtOH); IR (nujol):  3306, 1643 cm-1; 1H NMR (DMSO-d6):  9.71 (1H, d, J = 4.6 Hz, H-7), 9.38 
(1H, d, J = 8.6 Hz, H-9), 8.95 (1H, s, H-10), 8.61 (2H, m, H-2’, 6’), 7.96 (1H, dd, J = 8.6 and 4.6 Hz, 
H-8), 7.71 (3H, m, H-3’, 4’, 5’), 4.18 (3H, s, CH3), 3.82 (2H, s, CH2). 13C-NMR (DMSO-d6): δ 44.6 
(CH2), 49.8 (CH3), 109.6 (CH), 123.7 (CH), 125.6 (CH), 126.8 (C), 128.1 (2 x CH), 128.9 (C), 130.2 
(2 x CH), 132.4 (C), 135.3 (C), 136.6 (C), 135.8 (CH), 139.5 (C), 147.5 (CH), 150.6 (C), 181.5 (C). 
LC/MS: m/z 338 [M + 1]. Anal. Calcd. for C19H14ClN3O: C, 67.96; H, 4.20; N, 12.51; found C, 
68.25; H, 4.07; N, 12.81. 
 
4.1.8.2. 5-chloro-3-isopropyl-1-methylpyrido[2,3-g]quinoxalin-2(1H)-one (17) and 5-chloro-3-
isopropyl-2-methoxypyrido[2,3-g]quinoxaline (20) 
17 was obtained, in 27 % yield by the protocol described in the general procedure starting from 3 
[13]. M.p. 261-263 °C (from EtOH); IR (nujol):  3319, 1632 cm-1; 1H NMR (DMSO-d6):  8.71 
(1H, d, J = 4.0 Hz, H-7), 8.38 (1H, d, J = 7.2 Hz, H-9), 7.91 (1H, s, H-10), 7.74 (1H, dd, J = 7.2 and 
4.0 Hz, H-8), 3.61 (1H, m, CH), 3.48 (3H, s, N-CH3), 1.32 (6H, d, J = 6.4 Hz, 2 x CH3). 13C-NMR 
(CDCl3): δ 18.2 (2 x CH3), 37.8 (CH3), 39.6 (CH), 109.3 (CH), 123.3 (CH), 125.1 (C), 127.7 (C), 
133.2 (CH), 134.3 (C), 135.2 (C), 140.9 (C), 145.3 (CH), 154.6 (C), 155.2 (C). LC/MS: m/z 290 [M 
+ 1]. Anal. Calcd. for C15H14ClN3O: C, 62.61; H, 4.90; N, 14.60; found C, 62.38; H, 4.80; N, 14.34. 
20 was obtained from 3 in 18 % yield by the protocol above described. M.p 153-155 °C (from 
EtOH); IR (nujol):  3342, 1629 cm-1; 1H NMR (DMSO-d6):  8.64 (1H, d, J = 4.0 Hz, H-7), 8.60 
(1H, d, J = 7.2 Hz, H-9), 8.04 (1H, s, H-10), 7.82 (1H, dd, J = 7.2 Hz and J = 4.0, H-8), 4.21 (s, 3H, 
OCH3), 3.61 (1H, m, CH), 1.32 (6H, d, J = 6.4 Hz, 2 x CH3). 13C-NMR (DMSO-d6): δ 19.2 (2 x 
CH3), 39.7 (CH), 54.1 (CH3), 123.0 (CH), 124.9 (C), 126.9 (CH), 128.3 (C), 132.6 (CH), 135.2 (C), 
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136.1 (C), 142.0 (C), 147.6 (C), 149.3 (CH), 181.8 (C). LC/MS: m/z 290 [M + 1]. Anal. Calcd. for 
C15H14ClN3O: C, 62.61; H, 4.90; N, 14.60; found C, 62.57; H, 5.12; N, 14.91. 
 
4.1.8.3. 5-chloro-1-methyl-3-(thiophen-2-yl)pyrido[2,3-g]quinoxalin-2(1H)-one (18) and 5-chloro-
2-methoxy-3-(thiophen-2-yl)pyrido[2,3-g]quinoxaline (21) 
18 was obtained in 30 % yield by the protocol described in the general procedure starting from 4. 
M.p. 247-249 °C (from EtOH); IR (nujol):  3300, 1652 cm-1; 1H NMR (CDCl3):  9.01 (1H, d, J = 
4.0 Hz, H-7), 8.50 (1H, d, J = 7.0 Hz, H-5’), 8.47 (1H, d, J = 8.0 Hz, H-9), 8.04 (1H, s, H-10), 7.96 
(1H, d, J = 4.2 Hz, H-3’), 7.67 (1H, dd, J = 8.0 and 4.0 Hz, H-8), 7.31 (1H, dd, J = 7.0 and 4.2 Hz, 
H-4’), 3.77 (3H, s, CH3). 13C-NMR (CDCl3): δ 41.58 (CH3), 109.4 (CH), 122.6 (CH), 124.0 (C), 
125.1 (CH), 125.7 (C), 127.2 (CH), 127.5 (CH), 127.9 (C), 132.7 (CH), 134.4 (C), 135.7 (C), 140.2 
(C), 145.6 (CH), 153.8 (C), 157.6 (C). LC/MS: m/z 330 [M + 1]. Anal. Calcd. for C16H10ClN3OS: C, 
58.63; H, 3.07; N, 12.82; found C, 58.96; H, 2.91; N, 12.68. 
21was obtained from 4 in 13 % yield by the protocol above described. M.p. 148-150 °C (from 
EtOH); IR (nujol):  3321, 1663 cm-1; 1H NMR (CDCl3):  9.07 (1H, d, J = 4.4 Hz, H-7), 8.34 (1H, 
d, J = 7.0 Hz, H-5’), 8.32 (1H, d, J = 8.0 Hz, H-9), 8.07 (1H, s, H-10), 7.61 (1H, d, J = 4.2 Hz, H-3’), 
7.41 (1H, dd, J = 8.0 and 4.4 Hz, H-8), 7.15 (1H, dd, J = 7.0 and 4.2 Hz, H-4’), 4.23 (3H, s, CH3). 
13C-NMR (CDCl3): δ 54.26 (CH3), 109.1 (CH), 124.0 (CH), 125.8 (C), 126.3 (CH), 126.8 (C), 128.3 
(CH), 128.6 (CH), 129.1 (C), 134.2 (CH), 136.6 (C), 138.2 (C), 139.8 (C), 144.9 (C), 149.4 (CH), 
158.2 (C). LC/MS: m/z 330 [M + 1]. Anal. Calcd. for C16H10ClN3OS: C, 58.63; H, 3.07; N, 12.82; 
found C, 59.01; H, 2.86; N, 12.94. 
 
4.2. Biology  
4.2.1 Test compounds 
Compounds were dissolved in DMSO at 100 mM, and then diluted in culture medium. 
4.2.2. Cells and Viruses 
Cell lines were purchased from American Type Culture Collection (ATCC). The absence of 
mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines 
supporting the multiplication of RNA and DNA viruses were the following: CD4+ human T-cells 
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containing an integrated HTLV-1 genome (MT-4); Madin Darby Bovine Kidney (MDBK) [ATCC 
CCL22 (NBL-1) Bos Taurus], Baby Hamster Kidney (BHK-21) [ATCC CCL10 (C-13) 
Mesocricetusauratus] and Monkey kidney (Vero 76) [ATCCCRL 1587 CercopithecusAethiops]. 
Viruses were purchased from American Type Culture Collection (ATCC), with the exception of 
Yellow Fever Virus (YFV) and Human Immunodeficiency Virus type-1 (HIV-1). Viruses 
representative of positive-sense single stranded RNAs (ssRNA+) were: (i) Retroviridae: the IIIB 
laboratory strain of HIV-1, obtained from the supernatant of the persistently infected H9/IIIB cells 
(NIH 1983); (ii) Flaviviridae: yellow fever virus (YFV) [strain 17-D vaccine (Stamaril Pasteur 
J07B01)] and bovine viral diarrhoea virus (BVDV) [strain NADL (ATCC VR-534)]; (iii) 
Picornaviridae: human enterovirus B [coxsackie type B5 (CV-B5), strain Faulkner, (ATCC VR-
185)], and human enterovirus C [poliovirus type-1 (Sb-1), Sabin strain Chat (ATCC VR-1562)]. 
Viruses representative of negative-sense, single-stranded RNAs (ssRNA-) were: (iv) 
Paramyxoviridae: human respiratory syncytial virus (RSV) [strain A2 (ATCC VR-1540)]; (v) 
Rhabdoviridae: vesicular stomatitis virus (VSV) [lab strain Indiana (ATCC VR 158)]. The virus 
representative of double-stranded RNAs (dsRNA) Reoviridae was reovirus type-1 (Reo-1) [simian 
virus 12, strain 3651 (ATCC VR- 214)]. DNA virus representatives were: (vi) Poxviridae: vaccinia 
virus (VV) [strain Elstree (Lister Vaccine) (ATCC VR-1549)]; and (vii) Herpesviridae: human 
herpesvirus 1 (HSV-1) [strain KOS (ATCC VR- 1493)]. 
 
4.2.3. Cytotoxicity Assays 
Cytotoxicity assays were run in parallel with antiviral assays. Exponentially growing MT-4 cells 
were seeded at an initial density of 1x105 cells/mL in 96-well plates in RPMI-1640 medium, 
supplemented with 10% foetal bovine serum (FBS), 100 units/mL penicillin G and 100 mg/mL 
streptomycin. Cell cultures were then incubated at 37 °C in a humidified, 5% CO2 atmosphere, in 
the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 
h at 37 °C by the 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method 
[39]. MDBK and BHK cells were seeded in 96-well plates at an initial density of 6x105 and 1x106 
cells/mL, respectively, in Minimum Essential Medium with Earle’s salts (MEM-E), L-glutamine, 1 
mM sodium pyruvate and 25 mg/L kanamycin, supplemented with 10% horse serum (MDBK) or 
10% foetal bovine serum (FBS) (BHK). Cell cultures were then incubated at 37 °C in a humidified, 
5% CO2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability 
was determined after 72 hrs at 37 °C by the MTT method [39]. Vero-76 cells were seeded in 96-
well plates at an initial density of 4x105 cells/mL, in Dulbecco’s Modified Eagle Medium (D-
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MEM) with L-glutamine and 25 mg/L kanamycin, supplemented with 10% FBS. Cell cultures were 
then incubated at 37 °C in a humidified, 5% CO2 atmosphere in the absence or presence of serial 
dilutions of test compounds. Cell viability was determined after 48-96 h at 37 °C by the MTT 
method. 
 
4.2.4. Antiviral assays 
Antiviral activity against HIV-1 was based on inhibition of virus-induced cytopathogenicity in MT-
4 cells acutely infected with a multiplicity of infection (m.o.i.) of 0.01. Briefly, 50 µL of RPMI 
containing 1x104 MT-4 cells were added to each well of flat bottom microtitre trays, containing 50 
µL of RPMI without or with serial dilutions of test compounds. Then, 20 µL of a HIV-1 suspension 
containing 100 CCID50 were added. After a 4-day incubation at 37 °C, cell viability was determined 
by the MTT method. Antiviral activity against YFV and Reo-1 was based on inhibition of virus-
induced cytopathogenicity in BHK-21 cells acutely infected with am.o.i. of 0.01. Activity of 
compounds activity against BVDV was based on inhibition of virus-induced cytopathogenicity in 
MDBK cells acutely infected with am.o.i. of 0.01. Briefly, BHK and MDBK cells were seeded in 
96-well plates at a density of 5x104 and 3x104 cells/well, respectively, and were allowed to form 
confluent monolayers by incubating overnight in growth medium at 37 °C in a humidified CO2 
(5%) atmosphere. Cell monolayers were then infected with 50 µL of a proper virus dilution in 
maintenance medium [MEM-Earl with L-glutamine, 1 mM sodium pyruvate and 0.025 g/L 
kanamycin, supplemented with 0.5% inactivated FBS] to give an m.o.i of 0.01. After 2 hrs, 50 µL 
of maintenance medium, without or with serial dilutions of test compounds, were added. After a 3-
/4-day incubation at 37 °C, cell viability was determined by the MTT method [39].  
Antiviral activity against CVB-5, Sb-1, VV, HSV-1, VSV and RSV was determined by plaque 
reduction assays in infected cell monolayers. To this end, Vero 76-cells were seeded in 24-well 
plates at a density of 2x105 cells/well and were allowed to form confluent monolayers by incubating 
overnight in growth medium [Dulbecco’s Modified Eagle Medium (D-MEM) with L-glutamine and 
4500 mg/L D-glucose and 0.025 g/L kanamycin, supplemented with 10% FBS] at 37 °C in a 
humidified CO2 (5%) atmosphere. Then, monolayers were infected for 2 h with 250 µL of proper 
virus dilutions to give 50 to 100 PFU/well. Following removal of unadsorbed virus, 500 µL of 
maintenance medium [D-MEM with L-glutamine and 4500 mg/L Dglucose, supplemented with 1% 
inactivated FBS] containing 0.75% methylecellulose, without or with serial dilutions of test 
compounds, were added. Cultures were incubated at 37 °C for 2 (Sb-1 and VSV), 3 (CVB-5, VV 
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and HSV-1) or 5 days (RSV) and then fixed with PBS containing 50% ethanol and 0.8% crystal 
violet, washed and air-dried. Plaques were then counted. 
 
4.2.5. Linear regression analysis 
The extent of cell growth/viability and viral multiplication, at each drug concentration tested, were 
expressed as percentage of untreated controls. Concentrations resulting in 50% inhibition (CC50 or 
EC50) were determined by linear regression analysis. 
 
4.2.6. HCV replicon assay 
A human hepatoma cell line (Huh-7) bearing the HCV genotype 1b replicon (GS4.1 cells), kindly 
provided by C. Seeger (Fox Chase University, Philadelphia, PA, USA) through Idenix 
Pharmaceuticals, was grown in D-MEM supplemented with 10% FBS, 2 mM L-glutamine, 110 
mg/L sodium pyruvate, 0.1 mM non-essential amino acids, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.5 mg/mL G418 (Invitrogen). For dose-response testing, GS4.1 cells were seeded 
in 96-well plates at a density of 7.5 x 103 cells/well in 50 µL medium containing twofold serial 
dilutions of test compounds (highest concentration, 75 µM). Huh-7 cells lacking the HCV replicon 
served as negative controls. Plates were then incubated for 72 h at 37°C in a humidified, 5% CO2 
incubator. Inhibition of HCV replication was measured by quantification of the viral NS4A protein 
using an enzyme-linked immunosorbent assay (ELISA) as follows: plates were fixed for 1 min with 
1:1 acetone–methanol, washed twice with PBS containing 0.1% Tween 20, left for 1 h at room 
temperature with TNE buffer containing 10% FBS, and then incubated for 2 h at 37°C with the anti-
NS4A mouse monoclonal antibody A-236 (ViroGen, Watertown, MA, USA) diluted in the same 
buffer. After three washes with PBS containing 0.1% Tween 20, plates were incubated for 1 h at 
37°C with anti-mouse immunoglobulin G-peroxidase conjugate in TNE buffer containing 10% 
FBS. After further washing as above, the reaction was developed with phenylenediamine (Zymed, 
San Francisco, CA, USA). The reaction was stopped after 30 min with 2 N H2SO4 and absorbance 
was determined at 492 nm using a Sunrise Tecan (Durham, NC, USA) spectrophotometer. EC50 
values were determined from % inhibition vs compound concentration data, using a sigmoidal non-
linear regression analysis based on four parameters, with a Tecan Magellan software. For 
cytotoxicity evaluation, Huh-7 and GS4.1 cells were treated with compounds as described above, 
and cellular viability was monitored using the Cell Titer 96 Aqueous One Solution cell proliferation 
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assay (Promega). CC50 values were determined from the % cytotoxicity versus compound 
concentration data with Tecan Magellan software, as described above. 
4.2.7. Expression of the BVDV-NS5BD24 polymerase 
Expression and purification of BVDV-NS5B∆24 polymerase were performed as described in details 
in our previous work [13].  In brief, the expression plasmid encoding the His-tagged C-terminal 24-
aminoacid-deleted  BVDV-NS5B was introduced into the Escherichia coli strain Rosetta™ 
2(DE3)pLysS (Novagene) by chemical transformation. Transformant bacteria were cultured 
overnight at 30 C in 5 mL of lysogeny broth (LB) supplemented with 25 µg/mL kanamycin and 30 
µg/mL chloramphenicol. Cultures were then diluted into 1 L of LB medium additivated by the same 
quantities of the two antibiotics, and incubated at 30 C until the A600 reached 0.6–0.7. The culture 
was then induced overnight with 1 mM isopropyl-β-D-thiogalactopyranoside, after which cells were 
harvested by centrifugation and stored at 80 C until purification. 
4.2.8. Purification of NS5B proteins 
Cell pellets were thawed and immediately lysed by the addition of 10 mL of CelLytic B (Sigma). 
Insoluble material was removed by centrifugation at 11,000 rpm for 60 min at 4 C. The soluble 
extract was applied to a 5-mL column of nickel–nitrilotriacetic acid–agarose (Qiagen), previously 
equilibrated with the lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). The 
column was washed extensively with the wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0) and the protein was eluted stepwise with the elution buffer containing increasing 
concentration of imidazole (50 mM NaH2PO4, 300 mM NaCl, 50–250 mM imidazole, pH 8.0). The 
polypeptide composition of each column fraction was monitored via Coomassie-stained SDS–
PAGE analysis. Fractions enriched in pure 6xHis-tagged NS5B protein, recovered in the 130–250 
mM imidazole eluates, were pooled and dialyzed against a buffer containing 25 mM Tris–HCl, pH 
7.5, 2.5 mM MgCl2, 1 mM dithiothreitol, and 50% glycerol. Protein concentration was determined 
by the micro-Bradford method (Bio-Rad) using Bovine Serum Albumin (BSA) as standard. 
Following dialysis, the purified 6xHis-tagged BVDV-NS5B∆24 protein was divided into aliquots 
and stored at -80 C. 
4.2.9 RNA-dependent RNA polymerase assay 
Enzyme assays were performed in 96-well plates using 10 µg/mL poly(rC) (GE Healthcare, 
formerly Amersham Biosciences) as template, 0.1 µg/mL oligo(rG)12 (Invitrogen) as primer, and 
80 µM GTP (Invitrogen) as substrate, in a 20 µL reaction mixture containing 20 mM Tris/HCl, pH 
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7.0, 1 mM dithiothreitol, 25 mM NaCl, 20 U/mL RNasin (Promega), 5 mM MgCl2, 5% DMSO, 5% 
glycerol, and 500 ng of the purified protein. After enzyme/drug pre-incubation for 30 min at room 
temperature, reactions were started by the addition of GTP. One microliter of three-fold serial 
dilutions of test compounds in DMSO 0.5% were added, and the samples were incubated for 120 
min at 37 C (BVDV-NS5B∆24). DMSO alone or the nucleotide analog 30-deoxyguanosine-50-
triphosphate (30-dGTP) (tebu-bio) were used as negative and positive controls, respectively.  
Reactions were stopped by adding 2 µL of 200 mM EDTA. 138 microliters of the PicoGreen 
Quantitation Reagent Molecular Probes diluted 1:345 in TE (Tris/EDTA) buffer were added to each 
sample, followed by incubation for 5 min at room temperature in the dark. After excitation at 480 
nm, fluorescence was measured at 520 nm in a fluorescence microplate reader (Infinite F200, 
Tecan). Effective fluorescence was calculated by subtracting the mean fluorescence of the blank 
samples and by converting it into % of activity. Percent of residual activity was then plotted vs 
compound concentrations. Dose–response curves were fit with GraphPad Prism (v. 6.00 for 
Windows, GraphPad Software, La Jolla California US) to obtain the drug concentration providing 
50% inhibition (IC50). 
4.3. Computational details 
All simulations were carried out using the Pmemd modules of Amber 14 [40], running on own 
CPU/GPU calculation cluster. The entire MD simulation and data analysis procedure was optimized 
by integrating Amber 14 in modeFRONTIER, a multidisciplinary and multiobjective optimization 
and design environment [41]. Molecular graphics images were produced using the UCSF Chimera 
package (v.1.10) [42]. The interaction spectra in Figure 2A and 3A were obtained using GraphPad 
Prism version 6.00 for Mac OS X Yosemite, GraphPad Software, La Jolla California USA. 
4.3.1. Docking procedure 
The optimized structures of selected compounds 1-4, 14a, 15a, 16-18 and 19-21 were docked into 
the BVDV RdRp binding pockets using the optimized structure of the RdRp of BVDV taken from 
our previous work [23-29]. All docking experiments were performed with Autodock 4.3/Autodock 
Tools 1.4.6 [43] on a win64 platform. The resulting docked conformations were clustered and 
visualized; then, in the absence of any relevant crystallographic information, the structure of each 
resulting complex characterized by the lowest Autodock interaction energy in the prevailing cluster 
was selected for further modeling.  
4.3.2. Molecular Dynamics simulation 
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The inhibitor/RdRp complex obtained from the docking procedure was further refined in Amber 14 
[40] using the quenched molecular dynamics (QMD) method as previously described [23-38]. 
According to QMD, the best energy configuration of each complex resulting from this step was 
subsequently solvated by a cubic box of TIP3P [44] water molecules extending at least 10 Å in each 
direction from the solute. The system was neutralized and the solution ionic strength was adjusted 
to the physiological value of 0.15 M by adding the required amounts of Na+ and Cl- ions. Each 
solvated system was relaxed by 500 steps of steepest descent followed by 500 other conjugate-
gradient minimization steps and then gradually heated to a target temperature of 300 K in intervals 
of 50 ps of NVT MD, using a Verlet integration time step of 1.0 fs. The Langevin thermostat was 
used to control temperature, with a collision frequency of 2.0 ps_1. The protein was restrained with a 
force constant of 2.0 kcal/(mol Å), and all simulations were carried out with periodic boundary 
conditions. Subsequently, the density of the system was equilibrated via MD runs in the isothermal-
isobaric (NPT) ensemble, with isotropic position scaling and a pressure relaxation time of 1.0 ps, 
for 50 ps with a time step of 1 fs. All restraints on the protein atoms were then removed, and each 
system was further equilibrated using NPT MD runs at 300 K, with a pressure relaxation time of 2.0 
ps. Three equilibration steps were performed, each 4 ns long and with a time step of 2.0 fs. To 
check the system stability, the fluctuations of the root-mean-square-deviation (rmsd) of the 
simulated position of the backbone atoms of the BVDV RdRp protein with respect to those of the 
initial protein were monitored. All chemicophysical parameters and rmsd values showed very low 
fluctuations at the end of the equilibration process, indicating that the systems reached a true 
equilibrium condition. The equilibration phase was followed by a data production run consisting of 
50 ns of MD simulations in the canonical (NVT) ensemble. Only the last 20 ns of each equilibrated 
MD trajectory were considered for statistical data collections. A total of 1000 trajectory snapshots 
were analyzed the each molecule/polymerase complex.  
4.3.3. Free energy of binding analysis 
The binding free energy, ∆Gbind, between the selected compounds and the BVDV RdRp was 
estimated by resorting to the MM/PBSA approach implemented in Amber 14. According to this 
well validated methodology [23-38], the free energy was calculated for each molecular species 
(complex, protein, and ligand), and the binding free energy was computed as the difference: 
∆Gbind =  Gcomplex – (Gprotein + Gligand) = ∆EMM + ∆Gsol - T∆S 
in which ∆EMM represents the molecular mechanics energy, ∆Gsol includes the solvation free energy 
and T∆S is the conformational entropy upon ligand binding. The per residue binding free energy 
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decomposition was performed exploiting the MD trajectory of each given compound/BVDV RdRp 
complex, with the aim of identifying the key residues involved in the ligand/protein interaction. 
This analysis was carried out using the MM/GBSA approach [45, 46], and was based on the same 
snapshots used in the binding free energy calculation. 
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CAPTIONS 
 
Fig. 1. Chemical structure of lead compounds 1-4. 
Fig. 2. Dose–response curve for compound 21 obtained from in vitro enzyme assay with the BVDV 
RNA-dependent RNA polymerase. 
 
Fig.3. (A) Overall representation of the BVDV RdRp molecular surface with compound 21 docked 
into the protein putative binding site. The inhibitor is in orange sphere representation while the 
protein is represented by its different domains highlighted by different colors as follows: N-terminal 
(residues 92-138, red), Finger domain 1 (139-313, dim gray), Palm domain 1 (314-350, green), 
Finger domain 2 (351-410, dark slate gray), Palm domain 2 (411-500, spring green), and Thumb 
domain (501-679, dark slate blue). (B) Details of compound 21 in the RdRp binding pocket. 
Compound 21 is depicted as atom-colored sticks-and-balls (C, gray, N, blue, Cl, green, S, yellow) 
Hydrogen bonds are highlighted as black broken lines. The side chains of all residues that form the 
primary binding pocket interacting with 21 are highlighted as colored sticks: A221, I261, I287 and 
Y289, medium purple; R296, spring green; V216, Y303, V306, K307, P408 and A412, magenta; 
S411, chartreuse; Y674, green. In both panels, hydrogen atoms, water molecules, ions and 
counterions are omitted for clarity. 
 
Fig. 4. (A) Comparison of the per residue binding enthalpy decomposition ∆Hbind,res for compounds 
4, 18, and 21 in complex with the BVDV RdRp. Critical receptor residues are clustered according 
to the specific underlying interactions: HC (hydrophobic cavity) and HB (hydrogen bond) (see 
legend and main text for more details). (B) Superposition of equilibrated MD snapshots of the 
BVDV RdRp in complex with 21 (firebrick) and 4 (cyan). Hydrogen atoms, water molecules, ions 
and counterions are omitted for clarity. 
 
Fig. 5. (A) Comparison of per residue binding enthalpy decomposition for compounds 15a, 19, 20, 
and 21 in complex with the BVDV RdRp. Critical receptor residues are clustered according to the 
specific underlying interactions: HC (hydrophobic cavity) and HB (hydrogen bond). (see the legend 
and main text for more details). (B) Superposition of equilibrated MD snapshots of the BVDV 
RdRp in complex with 21 (firebrick) and 20 (olive drab). Hydrogen atoms, water molecules, ions 
and counterions are omitted for clarity. 
 
Fig. 6. (A) Comparison of the per residue binding enthalpy decomposition ∆Hbind,res for compounds 
21-25 in complex with the BVDV RdRp. Critical receptor residues are clustered according to the 
specific underlying interactions: HC (hydrophobic cavity) and HB (hydrogen bond) (see legend and 
main text for more details). (B) Superposition of equilibrated MD snapshots of the BVDV RdRp in 
complex with 21 (firebrick) and 25 (dark slate blue). Hydrogen atoms, water molecules, ions and 
counterions are omitted for clarity. 
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Scheme 1. Synthesis of lead compound 4. (i) H2SO4 10%, 60°C, 1h. 
Scheme 2. Synthesis of compounds 9a-c, 10b, 11a-c, 12b, and 13c. Reagents and conditions: (i) 
DMF, 100°C, 8h. (ii) 10% Pd/C, H2, EtOH. (iii) EtOH, reflux for 2 h to 12 h. 
Scheme 3. Synthesis of compounds 14a-e and 15a,b,e. Reagents and conditions: (a) (CH3)2SO4, 
DMF, Cs2CO3, 60°C for 16h. (b) (C2H5)2SO4, DMF, Cs2CO3, 60°C for 4h. (c) ClCH2CN, 60°C, 
Cs2CO3, for 1h. (d) BrCH2Ph, DMF, Cs2CO3, 60°C for 4h. (e) ClCH2-4-(NO2)Ph, DMF, Cs2CO3, 
60°C for 4h. 
Scheme 4. Synthesis of compounds 16-21. 
Table 1. Cytotoxicity and antiviral activity of pyrido[2,3-g]quinoxalines (1-4, 11a-c, 12b, 13c, 14a-
e, 15a,b,e, 16-21) and imidazo[4,5g]quinolines (9a-c and 10b) against ssRNA+ (HIV-1, BVDV, 
YFV, CV-5, Sb-1), ssRNA- (RSV, VSV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses. 
Table 2. Comparative activity of compounds 1, 2, and 4 against BVDV and HCV in cell-based 
assays. 
Table 3. Free energy components (∆Hbind and –T∆S) and total binding free energies (∆Gbind) for the 
12 selected compounds in complex with the BVDV RdRp. The last raw shows the correlation 
between the predicted ∆Gbind values (kcal/mol) and the corresponding experimental EC50 (µM) (R2 
= 0.89). 
Table 4. Clustered per-residue enthalpy contribution to binding (∆Hbind,res) for compound 21 in 
complex with the BVDV RdRp. All values are in kcal/mol. Errors are in the range 0.01–0.04. 
Table 5. Free energy components (∆Hbind and –T∆S) and total binding free energies (∆Gbind) for 21 
and the 4 new designed compounds in complex with the BVDV RdRp. 
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Table 1. Cytotoxicity and antiviral activity of pyrido[2,3-g]quinoxalines (1-4, 11a-c, 12b, 13c, 14a-e, 15a,b,e, 16-21) and imidazo[4,5g]quinolines 
(9a-c and 10b) against ssRNA+ (HIV-1, BVDV, YFV, CV-5, Sb-1), ssRNA- (RSV, VSV), dsRNA (Reo-1) and DNA (VV, HSV-1) viruses. 
Compd 
MT-4a HIV-1b MDBKc BVDVd BHK-21e YFVf Reo-1g Vero-76h CVB-5i Sb-1l RSVm VSVn VVo HSV-1p 
CC50 EC50 CC50 EC50 CC50 EC50 CC50 EC50 
1 61 >61 >100 5 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2 15 >15 >100 2.6 >100 >100 >100 88 >88 >88 >88 >88 >88 >88 
3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4 >100 >100 >100 5 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
9a 62 >62 >100 >100 >100 >100 >100 90 13 >90 >90 >90 >90 >90 
9b 50 >50 >100 29 >100 >100 67 35 >35 >35 >35 >35 >35 >35 
9c 10 >10 >100 10 71 >71 >71 25 >25 >25 >25 >25 >25 >25 
10b 18 >18 >100 65 45 >45 >45 15 >15 >15 >15 >15 >15 >15 
11a 40 >40 40 33 >100 >100 >100 50 7 >50 >50 >50 >50 >50 
11b 48 >48 >100 4 >100 >100 >100 70 >70 >70 >70 >70 >70 >70 
11c 23 >23 50 4 15 >15 >15 20 >20 >20 >20 >20 >20 >20 
12b >100 >100 >100 15 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
13c 34 >34 >100 5 20 >20 >20 20 >20 >20 >20 >20 >20 >20 
14a >100 >100 >100 16 >100 >100 >100 >100 17 38 >100 >100 >100 >100 
14b >100 >100 >100 >100 >100 >100 >100 60 >60 >60 >60 >60 >60 >60 
14c >100 >100 >100 >100 >100 >100 >100 90 >90 >90 >90 >90 >90 >90 
14d 88 >88 >100 46 >100 >100 >100 90 >90 >90 >90 >90 >90 >100 
14e >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
15a >100 >100 >100      4 >100 >100 21 >100 >100 73 9 >100 >100 >100 
15b >100 >100 >100 73 >100 >100 >100 50 >50 >50 >50 >50 >50 >50 
15e >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
16 >100 >100 >100 10 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
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17 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
18 >100 >100 >100 2 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
19 >100 >100 >100 6 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
20 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
21 >100 >100 >100 1.3 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
EFV 40 0.002             
Met-Gua   >100 1.1 >100 1.9         
Met-Cyt      >100 16        
Eth-Cyt        >100 27 23     
Aza        ≥12.5   1.2    
CDF        >100     19  
ACG        >100      3 
 
Data represent mean values for three independent determinations. Variation among duplicate samples was less than 15%. 
In bold the compounds with higher activity. 
ND = Not determined. 
a
 Compound concentration (µM) required to reduce the proliferation of mock-infected MT-4 cells by 50%, as determined by the MTT method. 
b Compound concentration (µM) required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity, as determined by the MTT method. 
c Compound concentration (µΜ) required to reduce the viability of mock-infected MDBK (Bovine normal kidney) cells by 50%, as determined by the MTT method. 
d
 Compound concentration (µM) required to achieve 50% protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. 
e
 Compound concentration (µΜ) required to reduce the viability of mock-infected BHK (Hamster normal kidney fibroblast) monolayers by 50%, as determined by the MTT 
method. 
f
 Compound concentration (µM) required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by the MTT method. 
g Compound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced cytopathogenicity, as determined by the MTT method. 
h Compound concentration (µM) required to reduce the viability of mock-infected VERO-76 cells by 50% as determined by the MTT method. 
i
 Compound concentration (µM) required to reduce the plaque number of CVB-5 by 50% in VERO-76 monolayers. 
l Compound concentration (µM) required to reduce the plaque number of Sb-1 by 50% in VERO-76 monolayers. 
m
 Compound concentration (µM) required to reduce the plaque number of RSV by 50% in VERO-76 monolayers. 
n
 Compound concentration (µM) required to reduce the plaque number of VSV by 50% in VERO-76 monolayers. 
o
 Compound concentration (µM) required to reduce the plaque number of VV by 50% in VERO-76 monolayers. 
p
 Compound concentration (µM) required to reduce the plaque number of HSV-1 by 50% in VERO-76 monolayers. 
EFV = Efavirenz 
MetGua = 2’-C-methyl-guanosine 
Met-Cyt = 2’-C-methyl-cytidine 
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Eth-Cyt= 2’-C-ethynyl-cytidine 
Aza = 6-aza-uridine 
CDF = Cidofovir 
ACG = Acycloguanosine 
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Table 2: Comparative activity of compounds 1, 2, and 4 against BVDV and HCV in cell-based assays. 
Cps Cell-baseda 
 BVDV   HCV-1b  
 (µM)   (µM)  
 CC50b EC50c S.I.  CC50d EC50e S.I. 
1 >100 5 ± 0.1 >20  11 ± 1.3 >11 1 
2 >100 2.6 ± 0.3 >34  65 ± 9.0 >65 1 
4 >100 6 ± 0.2 >16  21 ± 2.0 7.5±0.6 3 
 
Data represent mean values for three independent determinations. 
b Compound concentration (lM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. 
c Compound concentration (lM) required to achieve 50% protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. 
d Compound concentration (lM) required to reduce the viability of GS4.1 cells by 50%, as described in the Section 4.2.. 
e Compound concentration (lM) required to achieve 50% protection of GS4.1 cells from cytopathogenicity, as described in the Section 4.2. 
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Table 3. Free energy components (∆Hbind and –T∆S) and total binding free energies (∆Gbind) for the 12 selected 
compounds in complex with the BVDV RdRp. The last raw shows the correlation between the predicted ∆Gbind values 
(kcal/mol) and the corresponding experimental EC50 (µM) (R2 = 0.89). 
Scaffold Compound R ∆Hbind (kcal/mol) 
-T∆S 
(kcal/mol) 
∆Gbind 
(kcal/mol) 
 
1 Ph -21.50 (0.18) 
13.47 
(0.26) 
-8.03 
(0.32) 
2 Bz -21.58 (0.19) 
13.42 
(0.28) 
-8.16 
(0.34)  
3 CH(CH3)2 -18.33 (0.16) 
12.98 
(0.26) 
-5.35 
(0.31) 
4 2-Thienyl -21.39 (0.15) 
13.39 
(0.25) 
-8.00 
(0.29) 
 
14a Ph -20.97 (0.19) 
13.51 
(0.27) 
-7.46 
(0.33) 
16 Bz -21.10 (0.19) 
13.54 
(0.29) 
-7.56 
(0.35) 
17 CH(CH3)2 -18.34 (0.17) 
13.09 
(0.25) 
-5.25 
(0.30) 
18 2-Thienyl -21.36 (0.18) 
13.28 
(0.26) 
-8.08 
(0.32) 
 
15a Ph -21.37 (0.20) 
13.45 
(0.24) 
-7.92 
(0.31) 
19 Bz -21.42 (0.18) 
13.59 
(0.28) 
-7.83 
(0.33) 
20 CH(CH3)2 -18.28 (0.16) 
12.88 
(0.29) 
-5.40 
(0.33) 
21 2-Thienyl -21.56 (0.17) 
13.37 
(0.25) 
-8.19 
(0.30) 
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Table 4. Clustered per-residue enthalpy contribution to binding (∆Hbind,res) for compound 21 in 
complex with the BVDV RdRp. All values are in kcal/mol. Errors are in the range 0.01–0.04. 
Clustered 
energy HC1 HB1 HB2 HC2 HB3 
∆Hbind,res -2.98 -2.03 -1.98 -2.97 -0.58 
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Table 5. Free energy components (∆Hbind and –T∆S) and total binding free energies (∆Gbind) for 21 and the 4 new 
designed compounds in complex with the BVDV RdRp. 
 
Scaffold Compound R ∆Hbind (kcal/mol) 
-T∆S 
(kcal/mol) 
∆Gbind 
(kcal/mol) 
 
21 2-Thienyl 
-21.56 
(0.17) 
13.37 
(0.25) 
-8.19 
(0.30) 
22 Cyclohexyl 
-20.01 
(0.16) 
13.65 
(0.29) 
-6.36 
(0.33) 
23 2-Furanyl 
-21.85 
(0.15) 
13.42 
(0.27) 
-8.43 
(0.31) 
24 2-Naphtyl 
-21.63 
(0.18) 
13.49 
(0.26) 
-8.14 
(0.32) 
25 
2-
Benzofuranyl 
-22.12 
(0.15) 
13.40 
(0.25) 
-8.72 
(0.29) 
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Highlights 
In this study we prepared imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxaline derivatives.  
All derivates have been investigated for their antiviral activity.  
Several compounds showed micromolar activity against BVDV. 
Molecular simulation results offer a molecular rationale for the anti-BVDV activity.  
Some compounds were evaluated for their activity on the BVDV RdRp. 
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COMPOUND 14B - 1H-NMR 
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COMPOUND 14D - 1H-NMR 
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COMPOUND 14E - 1H-NMR 
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COMPOUND 15B - 1H-NMR 
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COMPOUND 14B – 13C-NMR 
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COMPOUND 14D – 13C-NMR 
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COMPOUND 14E – 13C-NMR 
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COMPOUND 15B – 13C-NMR 
 
 
